<SEC-DOCUMENT>0001193125-25-283182.txt : 20251114
<SEC-HEADER>0001193125-25-283182.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114163942
ACCESSION NUMBER:		0001193125-25-283182
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		23
CONFORMED PERIOD OF REPORT:	20251112
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			enGene Holdings Inc.
		CENTRAL INDEX KEY:			0001980845
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41854
		FILM NUMBER:		251487451

	BUSINESS ADDRESS:	
		STREET 1:		4868 RUE LEVY, SUITE 220
		CITY:			SAINT-LAURENT
		STATE:			A8
		ZIP:			H4R 2P1
		BUSINESS PHONE:		(514) 332-4888

	MAIL ADDRESS:	
		STREET 1:		4868 RUE LEVY, SUITE 220
		CITY:			SAINT-LAURENT
		STATE:			A8
		ZIP:			H4R 2P1
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d876714d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:engn="http://engene.com/20251112" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityTaxIdentificationNumber" name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-11-12_to_2025-11-12">00-0000000</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2025-11-12_to_2025-11-12" name="dei:EntityCentralIndexKey" contextRef="duration_2025-11-12_to_2025-11-12">0001980845</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2025-11-12_to_2025-11-12" name="dei:AmendmentFlag" contextRef="duration_2025-11-12_to_2025-11-12">false</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="engn-20251112.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-11-12_to_2025-11-12"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-12</xbrli:startDate> <xbrli:endDate>2025-11-12</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-12</xbrli:startDate> <xbrli:endDate>2025-11-12</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-12</xbrli:startDate> <xbrli:endDate>2025-11-12</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-11-12_to_2025-11-12" id="Fact_1">8-K</ix:nonNumeric></p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-11-12_to_2025-11-12" format="ixt:date-monthname-day-year-en" id="Fact_0">November 12, 2025</ix:nonNumeric></p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:EntityRegistrantName" id="ixv-373">enGene Holdings Inc.</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-11-12_to_2025-11-12" format="ixt-sec:edgarprovcountryen" id="Fact_2">British Columbia</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:EntityFileNumber" id="ixv-375">001-41854</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style=" -sec-ix-hidden:Hidden_dei_EntityTaxIdentificationNumber" id="Fact_3">Not applicable</span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr> </table><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:EntityAddressAddressLine1" id="ixv-376">4868 Rue Levy, Suite 220</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:EntityAddressCityOrTown" id="ixv-377">Saint-Laurent</ix:nonNumeric>, <ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="ixv-378">Quebec</ix:nonNumeric>, <ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="ixv-379">Canada</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:EntityAddressPostalZipCode" id="ixv-380">H4R&#160;2P1</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-11-12_to_2025-11-12" id="Fact_4">514</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-11-12_to_2025-11-12" id="Fact_5">332-4888</ix:nonNumeric></p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="ixv-383">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="ixv-384">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="ixv-385">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="ixv-386">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:Security12bTitle" id="ixv-387">Common Shares</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:TradingSymbol" id="ixv-388">ENGN</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-389">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember" name="dei:Security12bTitle" id="ixv-390">Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember" name="dei:TradingSymbol" id="ixv-391">ENGNW</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-392">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="ixv-393">&#9746;</ix:nonNumeric></p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <ix:nonNumeric contextRef="duration_2025-11-12_to_2025-11-12" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="ixv-394">&#9746;</ix:nonNumeric></p><p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement.</p></td></tr> </table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;12, 2025, enGene Holdings Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC, Leerink Partners LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), relating to the issuance and sale by the Company, in an underwritten public offering (the &#8220;Offering&#8221;) of 12,558,823 common shares of the Company, no par value per share (&#8220;Common Shares&#8221;), at a public offering price of $8.50 per Common Share, and <span style="white-space:nowrap">pre-funded</span> warrants to purchase 2,735,295 Common Shares (the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants&#8221;) at an offering price of $8.4999 per <span style="white-space:nowrap">Pre-Funded</span> Warrant, in each case before underwriting discounts and commissions. The aggregate gross proceeds to the Company from the Offering, before deducting the underwriting discounts and commissions and offering expenses payable by the Company, are approximately $130&#160;million. All securities sold in the Offering were offered by the Company. The Offering closed on November&#160;14, 2025. In addition, the Company also granted to the Underwriters a <span style="white-space:nowrap">30-day</span> option to purchase up to 2,294,117 additional Common Shares at the public offering price, less underwriting discounts and commissions (the &#8220;Option&#8221;).</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering was made pursuant to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-3&#160;(File</span>&#160;<span style="white-space:nowrap">No.&#160;333-283201),</span> which was filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on November&#160;13, 2024 and declared effective on November&#160;21, 2024, as supplemented by a prospectus supplement filed with the SEC pursuant to&#160;Rule 424(b) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <span style="white-space:nowrap">Pre-Funded</span> Warrant has an initial exercise price per share of $0.0001, subject to certain adjustments. The <span style="white-space:nowrap">Pre-Funded</span> Warrants may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a <span style="white-space:nowrap">Pre-Funded</span> Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the Company&#8217;s outstanding Common Shares immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of 19.99% (if exceeding such percentage would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule) upon 61 days&#8217; notice to the Company, subject to the terms of the <span style="white-space:nowrap">Pre-Funded</span> Warrants.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by such parties.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the terms of the Underwriting Agreement and <span style="white-space:nowrap">Pre-Funded</span> Warrants do not purport to be complete and are qualified in their entirety by reference to the Underwriting Agreement and form of <span style="white-space:nowrap">Pre-Funded</span> Warrant, which are filed as Exhibit 1.1 and Exhibit 4.1 hereto, respectively, and incorporated herein by reference. Copies of the opinion of Blake, Cassels&#160;&amp; Graydon LLP, with respect to matters of Canadian law, and Morgan, Lewis&#160;&amp; Bockius LLP, with respect to matters of U.S. law, are filed hereto as Exhibits 5.1 and 5.2, respectively.</p><p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td style="vertical-align:top;text-align:left"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure.</p></td></tr> </table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;12, 2025, the Company issued a press release entitled &#8220;enGene Announces Pricing of $130 Million Public Offering of Common Shares and <span style="white-space:nowrap">Pre-Funded</span> Warrants.&#8221; The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item&#160;7.01, including Exhibit&#160;99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits.</p></td></tr></table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(d) Exhibits </span></p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;text-align:center"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d876714dex11.htm">Underwriting Agreement, dated November&#160;12, 2025, by and among enGene Holdings Inc., Jefferies LLC, Leerink Partners LLC and Wells Fargo Securities, LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d876714dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d876714dex51.htm">Opinion of Blake, Cassels&#160;&amp; Graydon LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d876714dex52.htm">Opinion of Morgan, Lewis&#160;&amp; Bockius LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d876714dex51.htm">Consent of Blake, Cassels&#160;&amp; Graydon LLP (included in Exhibit&#160;5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d876714dex52.htm">Consent of Morgan, Lewis&#160;&amp; Bockius LLP (included in Exhibit&#160;5.2) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d876714dex991.htm">Press Release of enGene Holdings Inc. dated November&#160;12, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (Formatted as Inline XBRL)</td></tr></table><p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">
<tr>
<td style="width:44%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>
<td style="vertical-align:bottom"/>
<td style="width:5%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">ENGENE HOLDINGS INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: November&#160;14, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ronald H.W. Cooper</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Ronald H.W. Cooper</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer and President</td></tr></table></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d876714dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12,558,823 Shares </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase 2,735,295 Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">November&nbsp;12, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LEERINK PARTNERS LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WELLS FARGO SECURITIES, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o JEFFERIES
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street, 40th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02109 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Wells Fargo Securities, LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">375 Park Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10152 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc., a
company existing under the laws of the Province of British Columbia (the &#8220;<B>Company</B>&#8221;), proposes to issue and sell to the several underwriters named in <U>Schedule A</U> (the &#8220;<B>Underwriters</B>&#8221;) (i) an aggregate of
12,558,823 common shares, no par value (the &#8220;Shares&#8221;) and <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-funded</FONT> warrants to purchase an aggregate of 2,735,295 Shares in a form to be mutually agreed upon by the Company and the
Representatives (as defined below) (the &#8220;<B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</B>&#8221;). The 12,558,823 Shares to be sold by the Company are called the &#8220;<B>Firm Shares</B>&#8221; and together with the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to be sold by the Company are called the &#8220;<B>Firm Securities</B>.&#8221; In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,294,117 Shares
as provided in Section&nbsp;2. The additional 2,294,117 Shares to be sold by the Company pursuant to such option are collectively called the &#8220;<B>Optional Shares</B>.&#8221; The Firm Securities and, if and to the extent such option is
exercised, the Optional Shares are collectively called the &#8220;<B>Offered Securities</B>.&#8221; As used herein, &#8220;<B>Warrant Shares</B>&#8221; means the Shares issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants. Jefferies LLC (&#8220;Jefferies&#8221;), Leerink Partners LLC (&#8220;<B>Leerink Partners</B>&#8221;) and Wells Fargo Securities, LLC (&#8220;<B>Wells Fargo Securities</B>&#8221;) have agreed to act as representatives of the several
Underwriters (in such capacity, the &#8220;Representatives&#8221;) in connection with the offering and sale of the Offered Securities. To the extent there are no additional underwriters listed on <U>Schedule A</U>, the term
&#8220;Representatives&#8221; as used herein shall mean you, as Underwriters, and the term &#8220;Underwriters&#8221; shall mean either the singular or the plural, as the context requires. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed with the Securities and Exchange Commission (the
&#8220;Commission&#8221;) a shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> File <FONT STYLE="white-space:nowrap">No.&nbsp;333-283201,</FONT> including a base prospectus (the &#8220;<B>Base Prospectus</B>&#8221;) to
be used in connection with the public offering and sale of the Offered Securities. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the
Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the &#8220;<B>Securities Act</B>&#8221;), including all documents incorporated or deemed to be incorporated by reference therein and any
information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430A or 430B under the Securities Act, is called the &#8220;<B>Registration Statement</B>.&#8221; Any registration statement filed by the Company pursuant to Rule
462(b) under the Securities Act in connection with the offer and sale of the Offered Securities is called the &#8220;<B>Rule 462(b) Registration Statement</B>,&#8221; and from and after the date and time of filing of any such Rule 462(b)
Registration Statement the term &#8220;Registration Statement&#8221; shall include the Rule 462(b) Registration Statement. The preliminary prospectus supplement dated November&nbsp;12, 2025 describing the Firm Shares and the Optional Shares and the
offering thereof (the &#8220;<B>Preliminary Prospectus Supplement</B>&#8221;), together with the Base Prospectus, is called the &#8220;<B>Preliminary Prospectus</B>,&#8221; and the Preliminary Prospectus and any other prospectus supplement to the
Base Prospectus in preliminary form that describes the Offered Securities and the offering thereof and is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a &#8220;<B>preliminary
prospectus</B>.&#8221; As used herein, the term &#8220;<B>Prospectus</B>&#8221; shall mean the final prospectus supplement to the Base Prospectus that describes the Offered Securities and the offering thereof (the &#8220;<B>Final Prospectus
Supplement</B>&#8221;), together with the Base Prospectus, in the form first used by the Underwriters to confirm sales of the Offered Securities<B> </B>or in the form first made available to the Underwriters by the Company to meet requests of
purchasers pursuant to Rule 173 under the Securities Act. References herein to the Preliminary Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and the Base Prospectus components of such
prospectus. As used herein, &#8220;<B>Applicable Time</B>&#8221; is 9:20 p.m. (New York City time) on November&nbsp;12, 2025. As used herein, &#8220;<B>Time of Sale Prospectus</B>&#8221; means the Preliminary Prospectus, as amended or supplemented
immediately prior to the Applicable Time, together with the information included in <U>Schedule B</U> hereto. As used herein, <B>&#8220;Road Show&#8221;</B> means a &#8220;road show&#8221; (as defined in Rule 433 under the Securities Act) relating
to the offering of the Offered Securities contemplated hereby that is a &#8220;written communication&#8221; (as defined in Rule 405 under the Securities Act). As used herein, &#8220;<B>Section 5(d) Written Communication</B>&#8221; means each written
communication (within the meaning of Rule 405 under the Securities Act) that is made in reliance on Section&nbsp;5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company to one or more potential investors
that are qualified institutional buyers (&#8220;QIBs&#8221;) and/or institutions that are accredited investors (&#8220;IAIs&#8221;), as such terms are respectively defined in Rule 144A and Rule 501(a) under the Securities Act, to determine whether
such investors might have an interest in the offering of the Offered Securities; &#8220;<B>Section 5(d) Oral Communication</B>&#8221; means each oral communication, if any, made in reliance on Section&nbsp;5(d) of the Securities Act by the Company
or any person authorized to act on behalf of the Company made to one or more QIBs and/or one or more IAIs to determine whether such investors might have an interest in the offering of the Offered Securities; &#8220;<B>Marketing Materials</B>&#8221;
means any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Offered Securities, including any roadshow or investor presentations made to investors by the
Company (whether in person or electronically); and &#8220;<B>Permitted Section 5(d) Communication</B>&#8221; means the Section&nbsp;5(d) Written Communication(s) and Marketing Materials listed on Schedule C attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus
and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein. All references in this Agreement to financial statements and schedules and other information which are &#8220;contained,&#8221;
&#8220;included&#8221; or &#8220;stated&#8221; in, or &#8220;part of&#8221; the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus
or the Prospectus, and all other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
references of like import, shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the
Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. All references in this Agreement to
amendments or supplements to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any document under
the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &#8220;Exchange<B> Act&#8221;)</B> that is or is deemed to be incorporated by reference in the Registration Statement, the
Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, or the Prospectus, as the case may be. All references in this Agreement to (i)&nbsp;the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base
Prospectus or the Prospectus, any amendments or supplements to any of the foregoing, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (&#8220;EDGAR&#8221;) and
(ii)&nbsp;the Prospectus shall be deemed to include any &#8220;electronic Prospectus&#8221; provided for use in connection with the offering of the Offered Securities as contemplated by Section&nbsp;3(l) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company has only one subsidiary, then all references herein to &#8220;subsidiaries&#8221; of the Company shall be deemed
to refer to such single subsidiary, mutatis mutandis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the Underwriters as follows: <B>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1. </B>Representations and Warranties of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Representations and Warranties of the Company.</I></B> The Company hereby represents, warrants and covenants to each Underwriter, as of
the date of this Agreement, as of the First Closing Date (as hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Compliance with Registration Requirements.</I></B> The Registration Statement has become effective under the Securities Act.
The Company has complied, to the Commission&#8217;s satisfaction, with all requests of the Commission for additional or supplemental information, if any. No stop order suspending the effectiveness of the Registration Statement is in effect and no
proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. At the time the Company&#8217;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended October&nbsp;31, 2024 (the &#8220;<B>Annual Report</B>&#8221;) was filed with the Commission, or, if later, at the time the Registration Statement was originally filed with the
Commission, the Company met the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. The Company meets the requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under
the Securities Act specified in FINRA Conduct Rule 5110(B)(7)(C)(i). The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus, at the time they were or
hereafter are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Disclosure.</I></B> Each preliminary prospectus and the Prospectus when filed complied in all material respects with the
Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> under the Securities Act) to the copy thereof delivered to the
Underwriters for use in connection with the offer and sale of the Offered Securities. Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in all material
respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable
Time, the Time of Sale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospectus (including any preliminary prospectus wrapper) did not, and at the First Closing Date (as defined
in Section&nbsp;2) and at each applicable Option Closing Date (as defined in Section&nbsp;2), will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The Prospectus (including any Prospectus wrapper)<B>,</B> as of its date, did not, and at the First Closing Date and at each applicable Option Closing Date, will not, contain any untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the three
immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in
reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the Representatives expressly for use therein, it being understood and agreed that the only such information consists of the
information described in Section&nbsp;9(b) below. There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement which have not been
described or filed as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Free Writing Prospectuses</I></B><B>.</B> The Company is an &#8220;ineligible
issuer&#8221; in connection with the offering of the Offered Securities pursuant to Rules 164, 405 and 433 under the Securities Act. The Company has not, directly or indirectly, offered or sold any Offered Securities by means of any
&#8220;prospectus&#8221; (within the meaning of the Securities Act) or used any &#8220;prospectus&#8221; (within the meaning of the Securities Act) in connection with the offer or sale of the Offered Securities, in each case other than the
Preliminary Prospectus, the Time of Sale Prospectus or the Prospectus. The Company has not, directly or indirectly, prepared, used or referred to, and will not, directly or indirectly, prepare, use or refer to, any free writing prospectus (as
defined in Rule 405 under the Act) in connection with the offer and sale of the Offered Securities; and the Company was and is an &#8220;ineligible issuer&#8221; (as defined in Rule 405 under the Act) as of the time of filing the Registration
Statement and as of the time of each sale of the Offered Securities in connection with the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Distribution of
Offering Material By the Company</I></B><B>.</B> Prior to the later of (i)&nbsp;the expiration or termination of the option granted to the several Underwriters in Section&nbsp;2, and (ii)&nbsp;the completion of the Underwriters&#8217; distribution
of the Offered Securities<B>,</B> the Company has not distributed and will not distribute any offering material in connection with the offering and sale of the Offered Securities other than the Registration Statement, the Time of Sale Prospectus, or
the Prospectus reviewed and consented to by the Representatives, and any Permitted Section&nbsp;5(d) Communications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>The
Underwriting Agreement</I></B><B>.</B> This Agreement has been duly authorized, executed and delivered by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)
</B><B><I>Authorization of the Offered Securities</I></B><B>.</B> The Offered Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this
Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Offered Securities is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Offered
Shares. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been duly authorized by the Company and, when executed and delivered by the Company, will be valid and binding agreements of the Company, enforceable against the Company in
accordance with their terms, except to the extent the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general
equitable principles. The Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in a number sufficient to meet the current exercise requirements.
The Warrant Shares, when issued and delivered upon exercise of Pre-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Funded Warrants in accordance therewith, will be validly issued, fully paid and nonassessable (meaning that
the holder of Shares shall not, by reason of merely being such a holder, be subject to assessment or calls by the Company or its creditors for further payment on such Shares), and the issuance of the Warrant Shares is not subject to any preemptive
rights, rights of first refusal or other similar rights to subscribe for or purchase the Warrant Shares <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B><B></B><B><I>&nbsp;Parties to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B>.</B> The Company has furnished
to the Underwriters a letter agreement in the form attached hereto as <U>Exhibit A</U> (the &#8220;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement</B>&#8221;) from each of the persons listed on <U>Exhibit B</U>. Such <U>Exhibit B</U>
lists under an appropriate caption the directors and executive officers of the Company certain securityholders affiliated with directors of the Company. If any additional persons shall become directors or executive officers of the Company prior to
the end of the Company <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a director or executive officer of the
Company, to execute and deliver to the Representatives a <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)
</B><B><I>Statistical and Market-Related Data</I></B><B>.</B> All third-party statistical, demographic and market-related data included in the Registration Statement or the Prospectus are based on or derived from sources that the Company believes,
after reasonable inquiry, to be reliable and accurate in all material respects. To the extent required, the Company has obtained permission to use such data from such sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Disclosure Controls and Procedures; Deficiencies in or Changes to Internal </I></B><B><I>Control Over Financial
Reporting.</I></B> The Company has established and maintains disclosure controls and procedures (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which
(i)&nbsp;are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#8217;s principal executive officer and its principal financial officer by others within those
entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii)&nbsp;have been evaluated by management of the Company for effectiveness as of the end of the Company&#8217;s most recent
fiscal quarter; and (iii)&nbsp;except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, are effective in all material respects to perform the functions for which they were established. Except as
disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, since the end of the Company&#8217;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#8217;s
internal control over financial reporting (whether or not remediated) and no change in the Company&#8217;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s
internal control over financial reporting. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company is not aware of any change in its internal control over financial reporting that has occurred
during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>No Applicable Registration or Other Similar Rights.</I></B> There are no persons with registration or other similar rights to
have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>No Material Adverse Change.</I></B> Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus
and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus: (i)&nbsp;there has been no material adverse change, or any development that could
be expected to result in a material adverse change, in (A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">operations, operating results, assets, liabilities or prospects whether or not arising from transactions in
the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B)&nbsp;the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change
being referred to herein as a &#8220;<B>Material Adverse Change&#8221;);</B> (ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without
limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree,
that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any material transactions not in the ordinary course of business that are required to be disclosed in the
Registration Statement, the Time of Sale Prospectus or the Prospectus; and (iii)&nbsp;there has not been any material decrease in the share capital or any material increase in any short-term or long-term indebtedness of the Company or its
subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company&#8217;s subsidiaries on any class of share
capital, or any repurchase or redemption by the Company or any of its subsidiaries of any class of share capital, other than repurchases of unvested securities from officers, directors, employees, consultants, advisors or service providers of the
Company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>Independent Accountants.</I></B> KPMG LLP, an independent registered public
accounting firm, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement and the Prospectus,
is (i)&nbsp;an independent registered public accounting firm as required by the Securities Act, and the rules of the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;), (ii) in compliance with the applicable requirements relating to the
qualification of accountants under Rule <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose
registration has not been suspended or revoked and who has not requested such registration to be withdrawn. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Financial
Statements.</I></B> The financial statements filed with the Commission as a part of or incorporated by reference into the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly the consolidated financial position of
the Company and its subsidiaries in all material respects as of the dates indicated and the results of their operations, changes in stockholders&#8217; equity and cash flows for the periods specified. Such financial statements have been prepared in
conformity with generally accepted accounting principles, as applied in the United States, applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The interactive data in
eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and
guidelines applicable thereto. No other financial statements or supporting schedules are required to be included in the Registration Statement, the Time of Sale Prospectus or the Prospectus. The financial data set forth in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus fairly present the information set forth therein on a basis consistent with that of the audited financial statements contained in the Registration Statement, the Time of Sale Prospectus and
the Prospectus. To the Company&#8217;s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the
PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and
the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(n) </B><B><I>Company&#8217;s Accounting System.</I></B> The Company and each of its
subsidiaries make and keep accurate books and records in all material respects and maintain a system of internal accounting controls that are designed to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with
management&#8217;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles, as applied in the United States, and to
maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#8217;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at
reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Time of Sale
Prospectus and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B><I>Incorporation and Good Standing of the Company.</I></B> The Company is validly existing as a corporation in good standing
under the laws of the Province of British Columbia and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the Time of Sale Prospectus and to enter
into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the
ownership or leasing of property or the conduct of business, except where the failure to be so qualified could not be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(p) </B><B><I>Subsidiaries.</I></B> Each of the Company&#8217;s &#8220;subsidiaries&#8221; (for purposes of this Agreement, as defined in
Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of
its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus.
Each of the Company&#8217;s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such qualification is required,
whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified could not be expected, individually or in the aggregate, to result in a Material Adverse Change. All of the issued and
outstanding share capital or other equity or ownership interests of each of the Company&#8217;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through
subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the outstanding share capital or equity interest in any subsidiary was issued in violation of preemptive or similar rights of any
security holder of such subsidiary. The constitutive or organizational documents of each of the subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization and are in
full force and effect. The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21.1 to the Company&#8217;s most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(q) </B><B><I>Capitalization and Other Share Capital Matters.</I></B> The authorized, issued
and outstanding share capital of the Company is as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus (other than for subsequent issuances, if any, pursuant to employee benefit plans or upon the exercise of
outstanding options or warrants, in each case described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, or pursuant to warrants that may be issued in accordance with the terms of the Company&#8217;s existing debt
facility with Hercules Capital, Inc. that is described in the Registration Statement, the Time of Sale Prospectus and the Prospectus (the &#8220;<B>Disclosed Hercules Debt Facility</B>&#8221;). The Common Shares (including the Shares) conform in all
material respects to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the description thereof contained in the Prospectus. All of the issued and outstanding Common Shares have
been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws. None of the outstanding Common Shares was issued in violation of any preemptive rights, rights
of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt
securities convertible into or exchangeable or exercisable for, any share capital of the Company or any of its subsidiaries other than those described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and other than
warrants that may be issued in accordance with the terms of the Disclosed Hercules Debt Facility. The descriptions of the Company&#8217;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted
thereunder, set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus accurately and fairly presents in all material respects the information required to be shown with respect to such plans, arrangements, options and
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(r) </B><B><I>Stock Exchange Listing.</I></B> The Common Shares are registered pursuant to Section&nbsp;12(b) or 12(g) of the
Exchange Act and are listed on the Nasdaq Capital Market, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Shares under the Exchange Act or delisting the Common Shares from
the Nasdaq Capital Market, nor has the Company received any notification that the Commission or the Nasdaq Capital Market is contemplating terminating such registration or listing. To the Company&#8217;s knowledge, it is in compliance with all
applicable listing requirements of the Nasdaq Capital Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B><I><FONT STYLE="white-space:nowrap">Non-Contravention</FONT>
of Existing Instruments; No Further Authorizations or</I></B> <B><I>Approvals Required. </I></B>Neither the Company nor any of its subsidiaries is in violation of its charter or by laws, partnership agreement or operating agreement or similar
organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (&#8220;<B>Default</B>&#8221;) under any indenture, loan, credit agreement, note, lease, license agreement, contract,
franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its
subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject (each, an &#8220;<B>Existing Instrument</B>&#8221;), except for such Defaults as could not be expected,
individually or in the aggregate, to result in a Material Adverse Change. The Company&#8217;s execution, delivery and performance of this Agreement and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, consummation of the transactions
contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus and the issuance and sale of the Shares (including the use of proceeds from the sale of the Shares as described in the Registration Statement, the
Time of Sale Prospectus and the Prospectus under the caption &#8220;Use of Proceeds&#8221;) (i) have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the charter or by laws, partnership
agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary, (ii)&nbsp;will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below)
under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, or require the consent (except as may have been obtained by the Company) of any
other party to, any Existing Instrument and (iii)&nbsp;will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries. No consent, approval, authorization
or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#8217;s execution, delivery and performance of this Agreement and consummation of the transactions
contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act and such as may be required
under applicable state or provincial securities or blue sky laws or FINRA (as defined below). As used herein, a &#8220;<B>Debt Repayment Triggering Event</B>&#8221; means any event or<B><I> </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">condition which gives, or with the giving of notice or lapse of time would give, the holder of any note,
debenture or other evidence of indebtedness (or any person acting on such holder&#8217;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(t) </B><B><I>No Material Actions or Proceedings.</I></B> Except as otherwise disclosed in the Prospectus, there is no action, suit,
proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its subsidiaries, which could be expected, individually
or in the aggregate, to result in a Material Adverse Change. No material labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the
Company, exists or, to the knowledge of the Company, is threatened or imminent, which could be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(u) </B><B><I>Intellectual Property Rights.</I></B> Except as otherwise disclosed in the Registration Statement, the Time of Sale
Prospectus or the Prospectus, the Company and its subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other
intellectual property described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as being owned or licensed by them or which are necessary for the conduct of their respective businesses as currently conducted or as
currently proposed to be conducted (collectively, &#8220;<B>Intellectual Property</B>&#8221;), and, to the Company&#8217;s knowledge, the conduct of the respective businesses of the Company and its subsidiaries as currently conducted or as currently
proposed to be conducted does not and will not infringe, misappropriate or otherwise conflict in any material respect with any intellectual property rights of others. The Intellectual Property of the Company has not been adjudged by a court of
competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company&#8217;s knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party
licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus as licensed to the Company or one or more of its subsidiaries; and (ii)&nbsp;there is no infringement by
third parties of any Intellectual Property. There is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding, or claim asserted in writing, by others: (A)&nbsp;challenging the Company&#8217;s rights in or to any
Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property; or
(C)&nbsp;asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the Time of Sale Prospectus or the Prospectus as
under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others. The Company and its subsidiaries have complied with the terms of each agreement pursuant to which
Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are in full force and effect. To the Company&#8217;s knowledge, there are no material defects in any of the patents or patent applications included in
the Intellectual Property. The Company and its subsidiaries have taken reasonable steps to protect, maintain and safeguard their Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention
assignment agreements and invention assignments with their employees, and, to the Company&#8217;s knowledge, no employee of the Company is currently, or since October&nbsp;31, 2024 has been, in violation of any term of any employment contract,
patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement, or any restrictive covenant
to or with a former employer where the basis of such violation relates to such employee&#8217;s employment with the Company. To the Company&#8217;s knowledge, (i)&nbsp;the duty of candor and good faith as required by the United States Patent and
Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property have been complied with, and (ii)&nbsp;in all foreign offices having similar requirements, all
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such requirements have been complied with. None of the Company owned Intellectual Property or technology
(including information technology and outsourced arrangements) employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in material violation of any contractual obligation binding on the Company
or its subsidiaries or any of their respective officers, directors or employees or otherwise in material violation of the rights of any persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v) </B><B><I>All Necessary Permits, etc.</I></B> Except as otherwise disclosed in the Prospectus, the Company and each subsidiary possess
such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement, the Time
of Sale Prospectus or the Prospectus (&#8220;<B>Permits</B>&#8221;), except where the failure to possess any such Permit could not be expected, individually or in the aggregate, to result in a Material Adverse Change. Neither the Company nor any of
its subsidiaries is in material violation of, or in material default under, any of the Permits or has received any notice of proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-</FONT> compliance with,
any such certificate, authorization or permit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(w) </B><B><I>Title to Properties.</I></B> Except as otherwise disclosed in the
Prospectus, the Company and its subsidiaries have good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in <U>Section&nbsp;2(m)</U> above (or elsewhere in the
Registration Statement, the Time of Sale Prospectus or the Prospectus, in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except where the failure to comply with the
foregoing provisions of this Section&nbsp;2(w) with respect to any of such real or personal property or other assets could not be expected, individually or in the aggregate, to result in a Material Adverse Change. The real property, improvements,
equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made
of such real property, improvements, equipment or personal property by the Company or such subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(x) </B><B><I>Tax Law
Compliance.</I></B> The Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise tax returns, subject to permitted extensions (except where any failure to file any of such tax returns could not be
expected, individually or in the aggregate, to result in a Material Adverse Change) and have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them
except as may be being contested in good faith and by appropriate proceedings (except where any failure to pay could not be expected, individually or in the aggregate, to result in a Material Adverse Change). The Company has made adequate charges,
accruals and reserves in the applicable financial statements referred to in <U>Section&nbsp;2(m)</U> above in respect of all material federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company
or any of its subsidiaries has not been finally determined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> <B><I>Company Not an &#8220;Investment Company.&#8221;</I></B> The
Company is not, and will not be, either after receipt of payment for the Offered Securities or after the application of the proceeds therefrom as described under &#8220;Use of Proceeds&#8221; in the Registration Statement or the Prospectus, required
to register as an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended (the &#8220;<B>Investment</B> <B>Company Act</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(z) </B><B><I>Insurance.</I></B> Except as otherwise disclosed in the Prospectus, each of the Company and its subsidiaries are insured by
recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies
covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes. The Company has no reason to believe that it or any of its subsidiaries will not be able
(i) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain comparable
coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that could not be expected to result in a Material Adverse Change. Neither the Company nor any of its subsidiaries has been
denied any insurance coverage which it has sought or for which it has applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> <B><I>No Price Stabilization or Manipulation;
Compliance with Regulation M.</I></B> Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Common Shares or of
any &#8220;reference security&#8221; (as defined in Rule 100 of Regulation M under the Exchange Act (&#8220;<B>Regulation M</B>&#8221;)) with respect to the Common Shares, whether to facilitate the sale or resale of the Shares or otherwise, and has
taken no action which would directly or indirectly violate Regulation M. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(bb) </B><B><I>Related Party Transactions.</I></B> There are
no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus which have not been
described as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(cc) </B><B><I>FINRA Matters</I></B><B>.</B> All of the information provided to the Underwriters or to counsel
for the Underwriters by the Company, its counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the Offered Securities is true, complete, correct
and compliant with Financial Industry Regulatory Authority, Inc.&#8217;s (&#8220;<B>FINRA</B>&#8221;) rules and any letters, filings or other supplemental information provided by the Company for submission to FINRA pursuant to FINRA Rules or NASD
Conduct Rules is true, complete and correct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(dd) </B><B><I>No Unlawful Contributions or Other Payments.</I></B> Except as otherwise
disclosed in the Prospectus, neither the Company nor any of its subsidiaries nor, to the best of the Company&#8217;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or
candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ee) </B><B><I>Compliance with Environmental Laws.</I></B> Except as described in the Prospectus and except as could not be expected,
individually or in the aggregate, to result in a Material Adverse Change; (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or
rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without
limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes,
toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#8220;<B>Hazardous Materials</B>&#8221;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials (collectively, &#8220;<B>Environmental Laws</B>&#8221;), (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their
requirements, (iii)&nbsp;there are no pending or, to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or
proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (iv)&nbsp;to the knowledge of the Company, there are no events or circumstances that might reasonably be expected to form the basis of an order for <FONT
STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any
Environmental Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ff) </B><B><I>Costs of Environmental Compliance.</I></B> The Company is not required
pursuant to any Environmental Laws to incur costs (including, without limitation, any capital or operating expenditures) for <FONT STYLE="white-space:nowrap">clean-up,</FONT> closure of properties or compliance with Environmental Laws or in
connection with any permit, license or approval required under any such Environmental Laws that could be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(gg) </B><B><I>ERISA Compliance.</I></B> Except as otherwise disclosed in the Prospectus, the Company and its subsidiaries and any
&#8220;employee benefit plan&#8221; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#8220;<B>ERISA</B>&#8221;)) established or maintained
by the Company, its subsidiaries or their &#8220;ERISA Affiliates&#8221; (as defined below) are in compliance in all material respects with ERISA. &#8220;<B>ERISA Affiliate</B>&#8221; means, with respect to the Company or any of its subsidiaries,
any member of any group of organizations described in Sections 414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#8220;<B>Code</B>&#8221;) of which the
Company or such subsidiary is a member. No &#8220;reportable event&#8221; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any &#8220;employee benefit plan&#8221; established or maintained by the Company, its
subsidiaries or any of their ERISA Affiliates. No &#8220;employee benefit plan&#8221; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such &#8220;employee benefit plan&#8221; were terminated, would
have any &#8220;amount of unfunded benefit liabilities&#8221; (as defined under ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any material liability under (i)&nbsp;Title
IV of ERISA with respect to termination of, or withdrawal from, any &#8220;employee benefit plan&#8221; or (ii)&nbsp;Sections 412, 4971, 4975 or 4980B of the Code. Each &#8220;employee benefit plan&#8221; established or maintained by the Company,
its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act on the part of the Company, which would cause the
loss of such qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(hh) </B><B><I>Brokers.</I></B> Except as otherwise disclosed in the Prospectus, there is no broker,
finder or other party that is entitled to receive from the Company any brokerage or finder&#8217;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B><B><I>No Outstanding Loans or Other Extensions of Credit.</I></B> The Company does not have any outstanding extension of credit,
in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section&nbsp;13(k) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(jj) </B><B><I>Compliance with Laws.</I></B> The Company and its subsidiaries have been and are in compliance with all applicable laws,
rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(kk) </B><B><I>Dividend Restrictions.</I></B> Except as disclosed in the Prospectus, no subsidiary of the Company is prohibited or
restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary&#8217;s equity securities or from repaying to the Company or any other subsidiary of the Company any
amounts that may from time to time become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ll) </B><B><I>Anti-Corruption and Anti-Bribery Laws.</I></B> Neither the Company nor any of its subsidiaries nor any director, officer, or
employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, Affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the
Company or any of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">relating to political activity; (ii)&nbsp;made or taken any act in furtherance of an offer, promise, or
authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government- owned or controlled entity or public international organization, or any political party,
party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#8220;<B>FCPA</B>&#8221;), the Corruption of Foreign Public Officials Act
(Canada), as amended, and the rules and regulations thereunder (the &#8220;<B>CFPOA</B>&#8221;), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act
in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company&#8217;s Affiliates have conducted their
respective businesses in compliance with the FCPA and the CFPOA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(mm) </B><B><I>Money Laundering Laws.</I></B> The operations of the Company and its subsidiaries are, and have been conducted at all times,
in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), as amended,
the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively,
the &#8220;<B>Money Laundering Laws</B>&#8221;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money
Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(nn) </B><B><I>Clinical Data and Regulatory
Compliance</I></B><B>.</B> The preclinical tests and clinical trials, and other studies (collectively, &#8220;<B>studies</B>&#8221;) that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale
Prospectus or the Prospectus were, and, if still pending, are, being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and standard medical and scientific research
procedures; each description of the results of such studies in the Registration Statement, the Time of Sale Prospectus or the Prospectus is accurate and complete in all material respects and fairly presents the material data and results derived from
such studies, and the Company and its subsidiaries have no knowledge of any other studies involving the Company&#8217;s product candidates the results of which are inconsistent with, or otherwise call into question, the results described or referred
to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S.
Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the &#8220;<B>Regulatory
Agencies</B>&#8221;) in connection with the studies the results of which are referred to or disclosed in the Registration Statement, the Time of Sales Prospectus or the Prospectus; neither the Company nor any of its subsidiaries has received any
notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and
the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(oo) </B><B><I>Sanctions.</I></B> Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the knowledge
of the Company, after due inquiry, any agent, Affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of
the U.S. Department of the Treasury </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(&#8220;<B>OFAC</B>&#8221;) or the U.S. Department of State, the United Nations Security Council, the
European Union, His Majesty&#8217;s Treasury of the United Kingdom, or other relevant sanctions authority (collectively, &#8220;<B>Sanctions</B>&#8221;); nor is the Company or any of its subsidiaries located, organized or resident in a country or
territory that is the subject or the target of Sanctions, including, without limitation, the Crimea Region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#8217;s Republic, the
<FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#8217;s Republic, Cuba, Iran, North Korea, and Syria; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available
such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject
or the target of Sanctions or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. Since
April&nbsp;24, 2019, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target
of Sanctions or with any Sanctioned Country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(pp) </B><B><I>Sarbanes-Oxley.</I></B> The Company is in compliance, in all material
respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(qq)
</B><B><I>Duties, Transfer Taxes, Etc.</I></B> No stamp or other issuance or transfer taxes or duties and no capital gains, income, withholding or other taxes are payable by the Representatives in the United States or Canada or any political
subdivision or taxing authority thereof or therein in connection with the execution, delivery or performance of this Agreement by the Company or the sale and delivery by the Company of the Offered Securities, provided in all cases, however, that
each Underwriter (i)&nbsp;is not resident in Canada for purposes of the <I>Income Tax Act </I>(Canada), (ii) does not carry on business in Canada, (iii)&nbsp;does not render any services under this Agreement in Canada, (iv)&nbsp;does not render
services under this Agreement outside of Canada unless such services are performed in the ordinary course of a business carried on by such Underwriter that included the performance of such services for a fee; (v)&nbsp;deals at arm&#8217;s length
with the Company for purposes of the <I>Income Tax Act</I> (Canada); and (vi)&nbsp;is not a &#8220;specified shareholder&#8221; of the Company for purposes of subsection 18(5) of the <I>Income Tax Act </I>(Canada).<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(rr) </B><B><I>Cybersecurity.</I></B> The Company&#8217;s and its subsidiaries&#8217; information technology assets and equipment,
computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#8220;<B>IT</B><B> Systems&#8221;)</B> are adequate for, and operate and perform, in all material respects as required in connection with the
operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have implemented
and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and
security of all IT Systems and data, including &#8220;Personal Data,&#8221; used in connection with their businesses. &#8220;<B>Personal</B><B> Data&#8221;</B> means (i)&nbsp;a natural person&#8217;s name, street address, telephone number, <FONT
STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#8217;s license number, passport number, credit card number, bank information, or customer or account number; (ii)&nbsp;any
information which would qualify as &#8220;personally identifying information&#8221; under the Federal Trade Commission Act, as amended; (iii) &#8220;personal data&#8221; as defined by GDPR (as defined below); (iv) any information which would qualify
as &#8220;protected health information&#8221; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#8220;<B>HIPAA</B>&#8221;); and
(v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#8217;s health or sexual orientation. There have
been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">other person, nor any incidents under internal review or investigations relating to the same. The Company
and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual
obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ss) </B><B><I>Compliance with Data Privacy Laws.</I></B> The Company and its subsidiaries are, and since November&nbsp;1, 2024 have been,
in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply
with, and currently are in compliance with, the European Union General Data Protection Regulation (&#8220;<B>GDPR</B>&#8221;) (EU 2016/679) (collectively, the &#8220;<B>Privacy Laws</B>&#8221;). To ensure compliance with the Privacy Laws, the
Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection,
storage, use, disclosure, handling, and analysis of Personal Data (the &#8220;<B>Policies</B>&#8221;). The Company and its subsidiaries have made all disclosures to users or customers required by applicable laws and regulatory rules or requirements,
and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies
that neither it nor any subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws; (ii)&nbsp;is currently conducting or paying for, in whole or in
part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(tt) </B><B><I>Forward-Looking Statements.</I></B> No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities
Act and Section&nbsp;21E of the Exchange Act) (a &#8220;<B>Forward-Looking Statement</B>&#8221;) contained in the Registration Statement and the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in
good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(uu) </B><B><I>AMF.</I></B> The Company has received a valid approval of the <I>Autorit&eacute; des march&eacute;s
financiers </I>(&#8220;<B>AMF</B>&#8221;) pursuant to Section&nbsp;12 of the <I>Securities Act </I>(Qu&eacute;bec) with respect to the Base Prospectus, as supplemented by the Prospectus and the offering of Shares thereunder, and the AMF has not
withdrawn or modified such approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vv) </B><B><I>Outbound Investment Security Program.</I></B> Neither the Company nor any of its
subsidiaries is a &#8220;covered foreign person&#8221;, as that term is defined in 31 C.F.R. &#167; 850.209. Neither the Company nor any of its subsidiaries currently engages, or has plans to engage, directly or indirectly, in a &#8220;covered
activity&#8221;, as that term is defined in in 31 C.F.R. &#167; 850.208 (&#8220;<B>Covered Activity</B>&#8221;). The Company does not have any joint ventures that engages in or plans to engage in any Covered Activity. The Company also does not,
directly or indirectly, hold a board seat on, have a voting or equity interest in, or have any contractual power to direct or cause the direction of the management or policies of any person or persons that engages or plans to engage in any Covered
Activity.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to
counsel for the Underwriters pursuant to the requirements of this Agreement shall be deemed to be made by the Company only with respect to the statements specifically set forth in such certificate and only as of the date thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a reasonable basis for making each of the representations set forth in this
Section&nbsp;1. The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section&nbsp;7 hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy and truthfulness
of the foregoing representations and hereby consents to such reliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2. Purchase, Sale and Delivery of
the Offered Securities</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>The Firm Securities</I></B><B>.</B> Upon the terms herein set forth, the Company agrees to
issue and sell to the several Underwriters an aggregate of 12,558,823 Firm Shares and 2,735,295 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. On the basis of the representations, warranties and agreements herein contained, and upon
the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Company the respective number of Firm Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants set forth
opposite their names on <U>Schedule A</U>. The purchase price per Firm Share to be paid by the several Underwriters to the Company shall be $7.99 per share (the &#8220;<B>Share Purchase Price</B>&#8221;) and the purchase price per <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to be paid by the several Underwriters to the Company shall be $7.9899 (the &#8220;<B>Warrant Purchase Price</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>The First Closing Date</I></B><B>.</B> Delivery of certificates for the Firm Shares to be purchased by the Underwriters and
payment therefor shall be made at the offices of Cooley LLP, counsel for the Underwriters, at 55 Hudson Yards, New York, New York 10001 (or such other place as may be agreed to by the Company and the Representatives) at 9:00 a.m. New York City time,
on November&nbsp;14, 2025<B>,</B> or such other time and date not later than 1:30 p.m. New York City time, on November&nbsp;24, 2025 as the Representatives shall designate by notice to the Company (the time and date of such closing are called the
&#8220;<B>First Closing Date</B>&#8221;). The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to, any
determination by the Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section 12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>The Optional Shares; Option Closing Date</I></B><B>.</B> In addition, on the basis of the representations, warranties and
agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of 2,294,117 Optional Shares
from the Company at the purchase price per share to be paid by the Underwriters for the Firm Shares, less an amount per share equal to any dividend or distribution declared by the Company and payable on the Firm Shares but not payable on Optional
Shares. The option granted hereunder may be exercised at any time and from time to time in whole or in part upon notice by the Representatives to the Company which notice may be given at any time within 30 days from the date of this Agreement. Such
notice shall set forth (i)&nbsp;the aggregate number of Optional Shares as to which the Underwriters are exercising the option and (ii)&nbsp;the time, date and place at which certificates for the Optional Shares will be delivered (which time and
date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the First Closing Date, the term &#8220;<B>First Closing Date</B>&#8221; shall refer to the time and date of
delivery of certificates for the Firm Securities and such Optional Shares). Any such time and date of delivery, if subsequent to the First Closing Date, is called an &#8220;<B>Option Closing Date</B>,&#8221; and shall be determined by the
Representatives and shall not be earlier than two or later than five full business days after delivery of such notice of exercise. If any Optional Shares are to be purchased, each Underwriter agrees, severally and not jointly, to purchase the number
of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Optional Shares to be purchased as the number of Firm Shares set forth on
<U>Schedule A</U> opposite the name of such Underwriter bears to the total number of Firm Securities and (b)&nbsp;the Company agrees to sell the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the
Representatives may determine). The Representatives may cancel the option at any time prior to its expiration by giving written notice of such cancellation to the Company.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Public Offering of the Offered Securities</I></B><B>.</B> The
Representatives hereby advise the Company that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their respective portions of the
Offered Securities as soon after this Agreement has been executed as the Representatives, in their sole judgment, have determined is advisable and practicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Payment for the Offered Securities</I></B><B>.</B> Payment for the Offered Securities shall be made at the First Closing Date
(and, if applicable, at each Option Closing Date) by wire transfer of immediately available funds to the order of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) It is
understood that the Representatives have been authorized, for their own account and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares, the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and any Optional Shares the Underwriters have agreed to purchase. Each of Jefferies, Leerink Partners and Wells Fargo Securities individually and not as the Representatives of the Underwriters,
may (but shall not be obligated to) make payment for any Offered Securities to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the First Closing Date or the applicable Option Closing Date, as the
case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Delivery of the Offered Securities</I></B><B>.</B> The Company shall (i)&nbsp;deliver, or cause to be delivered to the
Representatives for the accounts of the several Underwriters certificates for the Firm Shares at the First Closing Date and (ii)&nbsp;deliver, or cause to be delivered to the purchaser(s) thereof the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants at the First Closing Date in accordance with the Representatives&#8217; instructions, in each case, following receipt of a wire transfer of immediately available funds for the amount of the
purchase price therefor. The Company shall also deliver, or cause to be delivered to the Representatives for the accounts of the several Underwriters, certificates for the Optional Shares the Underwriters have agreed to purchase at the First Closing
Date or the applicable Option Closing Date, as the case may be, following receipt of a wire transfer of immediately available funds for the amount of the purchase price therefor. If the Representatives so elect, delivery of the Offered Securities
may be made by credit to the accounts designated by the Representatives through The Depository Trust Company&#8217;s full fast transfer or DWAC programs. Notwithstanding the foregoing, the Company and the Representatives shall instruct purchasers of
the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to make payment for the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants on the First Closing Date to the Company by wire transfer in immediately available funds to the
account specified by the Company at a purchase price of $8.4999 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, in lieu of payment by the Underwriters for such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, and the
Company shall deliver the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to such purchasers on the First Closing Date in definitive form against such payment, in lieu of the Company&#8217;s obligation to deliver the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to the Representatives; provided that, the Underwriters shall withhold $0.5100 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant with respect to such
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants as an offset effected by the Company of its claim for payment by the Underwriters to the Company for the Firm Shares and Optional Shares (only to the extent the Underwriters&#8217; option
under Section&nbsp;2(c) hereof is exercised concurrently to close on the First Closing Date) against the Company&#8217;s obligation to pay the amount so withheld with respect to such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to the
Underwriters. In the event that any purchaser of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants fails to make payment to the Company for all or part of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants on the First
Closing Date, the Representatives shall either (i)&nbsp;make payment to the Company for such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants at the Warrant Purchase Price or (ii)&nbsp;elect, by written notice to the Company, to receive
Shares at the Share Purchase Price in lieu of all or a portion of such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants contemplated to be sold under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. Additional Covenants.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company further covenants and agrees with each Underwriter as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Delivery of Registration Statement, Time of Sale Prospectus and Prospectus.</I></B><I> </I>The Company shall furnish to you in
New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period when a prospectus relating to the Offered Securities is required by the Securities Act to be
delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Securities, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and
amendments thereto or to the Registration Statement as you may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Representatives&#8217; Review of
Proposed Amendments and Supplements.</I></B><I> </I>During the period when a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities
Act or any similar rule), the Company (i)&nbsp;will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each
such amendment or supplement and (ii)&nbsp;will not amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report filed under the Exchange Act) without the Representatives&#8217; prior
written consent. Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall
furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file or use any such
proposed amendment or supplement without the Representatives&#8217; prior written consent. The Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed
pursuant to such Rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Amendments and Supplements to Time of Sale Prospectus.</I></B><I> </I>If the Time of Sale
Prospectus is being used to solicit offers to buy the Offered Securities at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of which it is necessary to amend or
supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the opinion
of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section&nbsp;3(b) hereof) promptly prepare, file with the Commission and furnish, at its
own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or
supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Certain Notifications and Required Actions</I></B><B>.</B> After the date of this Agreement, the Company shall promptly
advise the Representatives in writing of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;the time and date of any filing of any post-effective amendment to the
Registration Statement or any amendment or supplement to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">any preliminary prospectus, the Time of Sale Prospectus, or the Prospectus; (iii)&nbsp;the time and date
that any post-effective amendment to the Registration Statement becomes effective; and (iv)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or
any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus, or the Prospectus, or of any
proceedings to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for
any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply
with all applicable provisions of Rule 424(b), Rule 433 and Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the
Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Amendments and Supplements to the Prospectus and Other Securities Act Matters.</I></B> If any event shall
occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading, or if in the opinion of the
Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section&nbsp;3(b)) hereof to promptly prepare, file with the Commission and
furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any
similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representatives&#8217; consent to, nor delivery of, any such amendment or supplement shall constitute a
waiver of any of the Company&#8217;s obligations under Section&nbsp;3(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Blue Sky Compliance</I></B><B>.</B> The
Company shall cooperate with the Representatives and counsel for the Underwriters to qualify or register the Offered Securities for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian
provincial securities laws (or other foreign laws) of those jurisdictions designated by the Representatives that are reasonably acceptable to the Company, shall comply with such laws and shall continue such qualifications, registrations and
exemptions in effect so long as required for the distribution of the Offered Securities. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such
jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption
relating to) the Offered Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or
exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment. Notwithstanding the foregoing or any other provision elsewhere in this Agreement to the contrary, no Shares will be offered or sold
in Canada, or knowingly to a person resident in Canada, pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Use of Proceeds</I></B><B>.</B> The Company shall apply the net proceeds
from the sale of the Offered Securities sold by it in the manner described under the caption &#8220;Use of Proceeds&#8221; in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>Transfer Agent</I></B><B>.</B> The Company shall engage and maintain, at its expense, a registrar and transfer agent for the
Firm Shares, the Optional Shares and the Warrant Shares. The Company may elect to engage and maintain, at its expense, a registrar and transfer agent for the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants or to act itself as the
registrar and transfer agent for the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>Earnings
Statement</I></B><B>.</B> The Company will make generally available to its security holders and to the Representatives as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning
with the first fiscal quarter of the Company commencing after the date of this Agreement that will satisfy the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Continued Compliance with Securities Laws</I></B><B>.</B> The Company will comply with the Securities Act and the Exchange
Act so as to permit the completion of the distribution of the Offered Securities as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing,
the Company will, during the period when a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on
a timely basis with the Commission and the NASDAQ all reports and documents required to be filed under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k)
</B><B><I>Listing</I></B><B>.</B> The Company will use its best efforts to list, subject to notice of issuance, the Offered Shares and the Warrant Shares on the NASDAQ. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>Company to Provide Copy of the Prospectus in Form That May be Downloaded from the Internet. </I></B>If requested by the
Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an &#8220;electronic Prospectus&#8221; to be used by the Underwriters in
connection with the offering and sale of the Offered Securities. As used herein, the term &#8220;electronic Prospectus&#8221; means a form of Prospectus, and any amendment or supplement thereto, that meets each of the following conditions:
(i)&nbsp;it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to offerees and purchasers of the Offered Securities; (ii)&nbsp;it
shall disclose the same information as the paper Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image material shall be replaced in the electronic Prospectus
with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or an electronic format, satisfactory to the Representatives, that will allow
investors to store and have continuously ready access to the Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and for <FONT STYLE="white-space:nowrap">on-line</FONT>
time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it was declared effective an undertaking that, upon
receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Agreement Not to Offer or Sell Additional Shares</I></B><B>.</B> During the
period commencing on and including the date hereof and continuing through and including the 90th day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &#8220;<B><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#8221;), the Company will not, without the prior written consent of the Representatives (which consent may be withheld in their sole discretion), directly or indirectly: (i)&nbsp;sell, offer to
sell, contract to sell or lend any Shares or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any &#8220;put equivalent position&#8221; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT>
under the Exchange Act) or liquidate or decrease any &#8220;call equivalent position&#8221; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act) of any Shares or Related Securities; (iii)&nbsp;pledge,
hypothecate or grant any security interest in any Shares or Related Securities; (iv)&nbsp;in any other way transfer or dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that
transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;publicly announce the offering of any
Shares or Related Securities (except that this clause (vi)&nbsp;shall not be construed or interpreted as prohibiting the filing a registration statement on Form <FONT STYLE="white-space:nowrap">S-8);</FONT> (vii) submit or file any registration
statement under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered Securities and other than a registration statement on Form
<FONT STYLE="white-space:nowrap">S-8);</FONT> (viii) effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Shares; or (ix)&nbsp;publicly announce the intention to do
any of the foregoing; <I>provided, however</I>, that the Company may (A)&nbsp;effect and publicly announce the transactions contemplated hereby; (B)&nbsp;issue Shares or options to purchase Shares, or issue Shares upon exercise, exchange or
conversion of Related Securities, pursuant to any stock option, stock bonus or other stock plan or arrangement, or pursuant to existing obligations described in the Registration Statement, the Time of Sale Prospectus and the Prospectus; and
(C)&nbsp;effect sales pursuant to the Open Market Sale AgreementSM, by and between the Company and Jefferies dated December&nbsp;20, 2024, provided that in the case of clause (C), no such sales may be made prior to the expiration of the Option
Period unless the option granted to the several Underwriters in Section&nbsp;2 has been exercised in full and all Optional Shares have been issued. For purposes of the foregoing, &#8220;<B>Related Securities</B>&#8221; shall mean any options or
warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(n) </B><B><I>Future Reports to the Representatives.</I></B><I> </I>During the period of five years hereafter, the Company will furnish to
the Representatives, c/o Jefferies LLC, at 520 Madison Avenue, New York, New York 10022, Attention: Global Head of Syndicate; c/o Leerink Partners LLC, at 1301 Avenue of the Americas, 5th Floor, New York, New York 10019, Attention: Stuart Nayman;
and c/o Wells Fargo Securities, LLC, at 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, Attention: Equity Syndicate Department (i)&nbsp;as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company
containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders&#8217;<I> </I>equity and cash flows for the year then ended and the opinion thereon of the Company&#8217;s independent public or
certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy statement, Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other report filed by the Company with the Commission, FINRA or any securities exchange; and (iii)&nbsp;as soon as available, copies
of any report or communication of the Company furnished or made available generally to holders of its share capital; <I>provided, however,</I> that the requirements of this Section&nbsp;3(n) shall be satisfied to the extent that such reports,
statement, communications, financial statements or other documents are available on EDGAR.<I> </I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B><I>Investment
Limitation</I></B><B>.</B> The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered Securities in such a manner as would require the Company or any of its subsidiaries to register as an
investment company under the Investment Company Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(p) </B><B><I>No Stabilization or Manipulation; Compliance with Regulation
M</I></B><B>.</B> The Company will not take, and will ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares or any
reference security with respect to the Shares, whether to facilitate the sale or resale of the Offered Securities or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation
M.&#8195; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(q) </B><B><I>Enforce <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B>.</B> During the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period, the Company will enforce all agreements between the Company and any of its securityholders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related
Securities or any of the other actions restricted or prohibited under the terms of the form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. In addition, the Company will direct the transfer agent to place stop transfer restrictions
upon any such securities of the Company that are bound by such <FONT STYLE="white-space:nowrap">&#8220;lock-up&#8221;</FONT> agreements for the duration of the periods contemplated in such agreements, including, without limitation, <FONT
STYLE="white-space:nowrap">&#8220;lock-up&#8221;</FONT> agreements entered into by the Company&#8217;s officers and directors and certain securityholders affiliated with directors of the Company pursuant to Section&nbsp;7(i) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(r) </B><B><I>Company to Provide Interim Financial Statements</I></B><B>.</B> Prior to the First Closing Date and each applicable Option
Closing Date, the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period subsequent to the period covered by
the most recent financial statements appearing in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(s) </B><B><I>Amendments and
Supplements to Permitted Section</I></B><B><I></I></B><B><I>&nbsp;5(d) Communications.</I></B> If at any time following the distribution of any Permitted Section&nbsp;5(d) Communication, there occurred or occurs an event or development as a result
of which such Permitted Section&nbsp;5(d) Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Permitted Section&nbsp;5(d) Communication to eliminate or correct
such untrue statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(t) </B><B><I>Emerging Growth Company Status.</I></B> The Company will promptly notify the
Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i)&nbsp;the time when a prospectus relating to the Offered Securities is not required by the Securities Act to be delivered (whether physically
or through compliance with Rule 172 under the Securities Act or any similar rule) and (ii)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined herein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(u) </B><B><I>Announcement Regarding <FONT STYLE="white-space:nowrap">Lock-ups</FONT></I></B><B>.</B> The Company agrees to announce the
Underwriters&#8217; intention to release any director or &#8220;officer&#8221; (within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> under the Exchange Act) of the Company from any of the restrictions imposed by any <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, by issuing, through a major news service, a press release in form and substance satisfactory to the Representatives or, if consented to by the Representatives, in a registration statement that is
publicly filed in connection with a secondary offering of the Company&#8217;s shares promptly following the Company&#8217;s receipt of any notification from the Representatives in which such intention is indicated, but in any case not later than the
close of the third business day prior to the date on which such release or waiver is to become effective; provided, however, that nothing shall prevent the Representatives, on behalf of the Underwriters, from announcing the same through a major news
service, irrespective of whether the Company has made the required announcement; and <I>provided</I>, <I>further</I>, that no such announcement shall be made of any release or waiver granted solely to permit a transfer of securities that is not for
consideration and where the transferee has agreed in writing to be bound by the terms of a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement in the form set forth as Exhibit A hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v) </B><B><I>Tax Indemnity. </I></B>The Company will indemnify and hold harmless the
Underwriters against any documentary, stamp, transfer, registration or other similar taxes or duties (for the avoidance of doubt, whether imposed in Canada or otherwise) (including any interest, penalties and additions to tax), on or in connection
with any transaction contemplated by this Agreement including (without limitation), (i) the authorization, preparation, issuance and delivery of the Shares by the Company to the Underwriters, (ii)&nbsp;the initial sale and delivery by the
Underwriters of the Shares to purchasers thereof, and (iii)&nbsp;the execution, delivery and performance of the Company or the Underwriters of this Agreement. All payments made by the Company under this Agreement will be made without withholding or
deduction for or on account of any present or future taxes, duties, assessment or governmental charges of whatever nature (other than taxes on net income) imposed or levied by or on behalf of any taxing authority unless the Company is compelled by
law to deduct or withhold such taxes, duties, assessments or charges. In that event, the Company shall, to the extent permitted by law, pay such additional amounts as may be necessary in order to ensure that the net amounts received by each
Underwriter after such withholding or deductions shall equal the amounts that would have been received if no withholding or deduction has been made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4. Payment of Expenses.</B> The Company agrees to pay all reasonable and documented costs, fees and expenses
incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and delivery of the Offered Securities
(including all printing and engraving costs), (ii) all fees and expenses of the registrar and transfer agent of the Offered Shares and Warrant Shares, (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance and
sale of the Offered Securities to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&#8217;s counsel, independent public or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with
the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, the Preliminary
Prospectus, each Permitted Section&nbsp;5(d) Communication, and all amendments and supplements thereto, and this Agreement, (vi)&nbsp;all filing fees, attorneys&#8217; fees and expenses incurred by the Company or the Underwriters in connection with
qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Offered Securities for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and,
if requested by the Representatives, preparing and printing a &#8220;Blue Sky Survey&#8221; or memorandum, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii)&nbsp;the costs, fees and
expenses incurred by the Underwriters in connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters&#8217; participation in the offering and distribution of the Offered Securities, including any
related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters (provided, however, that the aggregate amount reimbursable by the Company pursuant to clauses (vi)&nbsp;and (vii) shall not exceed $20,000)<B>,</B> (viii)
the costs and expenses of the Company relating to investor presentations on any &#8220;road show&#8221;, any Permitted Section&nbsp;5(d) Communication or any Section&nbsp;5(d) Oral Communication undertaken in connection with the offering of the
Offered Securities, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants
engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and the cost of any aircraft chartered
in connection with the road show, and (ix)&nbsp;the fees and expenses associated with listing the Offered Shares and the Warrant Shares on the NASDAQ. Except as provided in this Section&nbsp;4 or in Section&nbsp;8, Section&nbsp;10 or Section&nbsp;11
hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5. Warrant Shares Reserved.</B> The Company shall, at all
times while any <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are outstanding, reserve and keep available out of its authorized but unissued and otherwise unreserved Shares, solely for the purpose of enabling it to issue Warrant Shares
upon exercise of such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the number of Warrant Shares that are issuable and deliverable upon exercise of the then outstanding <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6. Covenant of the Underwriters.</B> Each Underwriter severally and not jointly covenants with the Company not
to take any action that would result in the Company (assuming it was not an ineligible issuer as defined under Rule 405 of the Securities Act) being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing
prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the Company under Rule 433(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7. Conditions of the Obligations of the Underwriters.</B> The respective obligations of the several Underwriters
hereunder to purchase and pay for the Offered Securities as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be subject to the accuracy of the representations and warranties on the
part of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option Closing Date as though then made, to the timely performance
by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B><B></B><B><I>&nbsp;Comfort Letter</I></B><B>.</B> On the date hereof, the Representatives shall have received from KPMG LLP,
independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representatives, containing statements and information of the type ordinarily included
in accountant&#8217;s &#8220;comfort letters&#8221; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the audited and unaudited financial statements and certain financial
information contained in the Registration Statement and the Time of Sale Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Compliance with Registration
Requirements; No Stop Order; No Objection from FINRA.</I></B> For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date,
each Option Closing Date:<B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;The Company shall have filed the Prospectus with the Commission (including the information
previously omitted from the Registration Statement pursuant to Rule 430B under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a post-effective amendment
to the Registration Statement containing the information previously omitted from the Registration Statement pursuant to such Rule 430B, and such post-effective amendment shall have become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement
shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) If a filing
has been made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>No Material Adverse Change or Ratings Agency Change</I></B><B>.</B> For the
period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) in the judgment of the Representatives there shall not have occurred any Material Adverse Change; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any
review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#8220;nationally recognized statistical rating organization&#8221; as
that term is used in Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Opinion and Negative Assurance Letter of Counsel
for the Company</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date the Representatives shall have received (i)&nbsp;the opinion and negative assurance letter of Morgan, Lewis&nbsp;&amp; Bockius LLP, U.S. counsel for the
Company, and (ii)&nbsp;the opinion of Blake, Cassels and Graydon LLP, Canadian counsel for the Company, in each case, dated as of such date, in form and substance reasonably satisfactory to the Representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Opinion of Intellectual Property Counsel for the Company.</I></B><I> </I>On each of the First Closing Date and each Option
Closing Date the Representatives shall have received the opinion of Squire Patton Boggs (US) LLP, intellectual property counsel for the Company, dated as of such date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Opinion and Negative Assurance Letter of Counsel for the Underwriters</I></B><B>.</B> On each of the First Closing Date and
each Option Closing Date the Representatives shall have received the opinion and negative assurance letter of Cooley LLP, counsel for the Underwriters in connection with the offer and sale of the Offered Securities, in form and substance
satisfactory to the Underwriters, dated as of such date.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Officers&#8217; Certificate</I></B><B>.</B> On each of
the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated as of such date, to
the effect set forth in Section&nbsp;7(b)(ii) and further to the effect that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;for the period from and including the date of this
Agreement through and including such date, there has not occurred any Material Adverse Change; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;the representations, warranties
and covenants of the Company set forth in Section&nbsp;1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or
satisfied hereunder at or prior to such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>Bring-down Comfort Letter</I></B><B>.</B> On each of the First Closing
Date and each Option Closing Date the Representatives shall have received from KPMG LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representatives, which letter
shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant to Section&nbsp;7(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to the
First Closing Date or the applicable Option Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information contained in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements.</I></B> On or prior to the date hereof, the Company shall have
furnished to the Representatives an agreement in the form of <U>Exhibit A</U> hereto from each of the persons listed on Exhibit E hereto, and each such agreement shall be in full force and effect on each of the First Closing Date and each Option
Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Rule 462(b) Registration Statement</I></B><B>.</B> In the event that a Rule
462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule 462(b) Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have become effective
automatically upon such filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>CFO Certificate</I></B><B>.</B> On the date of this Agreement and on the First Closing
Date or the applicable Option Closing Date, as the case may be, the Company shall have furnished to the Representatives a certificate, dated the respective dates of delivery thereof and addressed to the Underwriters, of its chief financial officer
with respect to certain financial data contained in the Time of Sale Prospectus and the Prospectus, providing &#8220;management comfort&#8221; with respect to such information, in form and substance reasonably satisfactory to the Representatives.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>Approval of Listing.</I></B> At the First Closing Date, the Offered Shares and the Warrant Shares shall have been
approved for listing on Nasdaq, subject only to official notice of issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Form of
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant.</I></B> The Representatives shall have received a form of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, in form and substance reasonably satisfactory to the
Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(n) </B><B><I>Additional Documents</I></B><B>.</B> On or before each of the First Closing Date and each Option
Closing Date, the Representatives and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Offered
Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in
connection with the issuance and sale of the Offered Securities as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for
the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any condition specified in this Section&nbsp;7 is not satisfied when and as required to be satisfied, this Agreement
may be terminated by the Representatives by notice to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall be
without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;8, Section&nbsp;10 and Section&nbsp;11 shall at all times be effective and shall survive such termination.&#8195; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8. Reimbursement of Underwriters&#8217; Expenses.</B> If this Agreement is terminated by the Representatives
pursuant to Section&nbsp;7, Section&nbsp;12 or Section&nbsp;13, or if the sale to the Underwriters of the Offered Securities on the First Closing Date is not consummated because of any refusal, inability or failure on the part of the Company to
perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves), severally, upon
demand for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses that shall have been reasonably incurred by the Representatives and the Underwriters in connection with the proposed purchase and
the offering and sale of the Offered Securities, including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9. Effectiveness of this Agreement.</B> This Agreement shall become effective upon the execution and delivery
hereof by the parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;10. Indemnification. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Indemnification of the Underwriters</I></B><B>.</B> The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which
such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign
jurisdictions where Offered Securities have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage,
liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto,
or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included
in any preliminary prospectus, the Time of Sale Prospectus, any Marketing Material, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein
a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading; or (iii)&nbsp;any act or failure to act or any alleged act or failure to act by any Underwriter in connection
with, or relating in any manner to, the Shares or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i)&nbsp;or
(ii) above; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by such
Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <I>provided,
however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or
alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of
Sale Prospectus, any Marketing Material, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the information described in
Section&nbsp;10(b) below. The indemnity agreement set forth in this Section&nbsp;10(a) shall be in addition to any liabilities that the Company may otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Indemnification of the Company, its Directors and Officers</I></B><B>.</B> Each Underwriter agrees, severally and not
jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act,
against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or
regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions in respect
thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time
of Sale Prospectus, any Section&nbsp;5(d) Written Communication or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in order to make </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue
statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such Section&nbsp;5(d) Written Communication or the Prospectus (or any such amendment or supplement), in
reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director, officer or controlling person for
any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or paying
any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Representatives has furnished to the Company expressly for use in the Registration Statement, any preliminary prospectus,
the Time of Sale Prospectus, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing) are the statements set forth in first sentence of the third paragraph, the first sentence of the first
paragraph under the section entitled &#8220;Commissions and Expenses,&#8221; the first sentence of the first paragraph under the section entitled &#8220;Stabilization,&#8221; and the first sentence of the first paragraph under the section entitled
&#8220;Electronic Distribution,&#8221; under the caption &#8220;Underwriting&#8221; in the Preliminary Prospectus Supplement and the Final Prospectus Supplement. The indemnity agreement set forth in this Section&nbsp;10(b) shall be in addition to
any liabilities that each Underwriter may otherwise have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Notifications and Other Indemnification
Procedures</I></B><B>.</B> Promptly after receipt by an indemnified party under this Section&nbsp;10 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party
under this Section&nbsp;9, notify the indemnifying party in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified
party to the extent the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity
agreement. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that
it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with
counsel reasonably satisfactory to such indemnified party; <I>provided, however</I>, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded
that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different
from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of
such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#8217;s election to so assume the defense of such action and approval by the indemnified party of counsel, the
indemnifying party will not be liable to such indemnified party under this Section&nbsp;9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party
shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with
local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the Representatives (in the case of counsel for the indemnified
parties referred to in 10(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in 10(b) above)) or (ii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to
represent the indemnified party within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying
party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Settlements</I></B><B>.</B> The indemnifying party under this
Section&nbsp;9 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the
indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the
indemnified party for fees and expenses of counsel as contemplated by Section&nbsp;10(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered
into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No
indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified
party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on
claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11. Contribution.</B> If the indemnification provided for in Section&nbsp;10 is for any reason held to be
unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or
payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the
one hand, and the Underwriters, on the other hand, from the offering of the Offered Securities pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which
resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with
the offering of the Offered Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Securities pursuant to this Agreement (before deducting expenses)
received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public offering price of the Offered
Securities as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a
material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties&#8217; relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses,
claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section&nbsp;10(c), any legal or other fees or expenses reasonably incurred by such party in connection with
investigating or defending any action or claim. The provisions set forth in Section&nbsp;10(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;11; <I>provided,
however,</I> that no additional notice shall be required with respect to any action for which notice has been given under Section&nbsp;10(c) for purposes of indemnification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it would not be just and equitable if
contribution pursuant to this Section&nbsp;11 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable
considerations referred to in this Section&nbsp;11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this Section&nbsp;11, no Underwriter shall be
required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Securities underwritten by it and distributed to the public. No person guilty of fraudulent
misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#8217; obligations to contribute pursuant
to this Section&nbsp;11 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on Schedule A. For purposes of this Section&nbsp;11, each affiliate, director, officer,
employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company,
each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12. Default of One or More of the Several Underwriters</B><B><I>.</I></B> If, on the First Closing Date or any
Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Securities that it or they have agreed to purchase hereunder on such date, and the aggregate number of Offered Securities which such defaulting
Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Securities to be purchased on such date, the Representatives may make arrangements satisfactory to the Company for the
purchase of such Offered Securities by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of
Firm Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants set forth opposite their respective names on <U>Schedule A</U> bears to the aggregate number of Firm Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants
set forth opposite the names of all such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, to purchase the Offered Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date. If, on the First Closing Date or any
Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Securities and the aggregate number of Offered Securities with respect to which such default occurs exceeds 10% of the aggregate number of Offered
Securities to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Offered Securities are not made within 48 hours after such default, this Agreement shall terminate without
liability of any party to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7, Section&nbsp;10 and Section&nbsp;11 shall at all times be effective and shall survive such termination. In any such case either the
Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the
Registration Statement and the Prospectus or any other documents or arrangements may be effected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the term
&#8220;<B>Underwriter</B>&#8221; shall be deemed to include any person substituted for a defaulting Underwriter under this Section&nbsp;12. Any action taken under this Section&nbsp;12 shall not relieve any defaulting Underwriter from liability in
respect of any default of such Underwriter under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13. Termination of this Agreement</B><B><I>.</I></B> Prior to
the purchase of the Firm Shares by the Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i)&nbsp;trading or quotation in any of the Company&#8217;s
securities shall have been suspended or limited by the Commission or by the NASDAQ, or trading in securities generally on either the NASDAQ or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally
established on any of such stock exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York, or British Columbia<B> </B>authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of
national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#8217; or
international political, financial or economic conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Securities in the manner and on the terms described in the Time of Sale
Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv)&nbsp;in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike,
fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have
been insured. Any termination pursuant to this Section&nbsp;13 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the
Underwriters pursuant to Section&nbsp;4 or Section&nbsp;8 hereof or (b)&nbsp;any Underwriter to the Company; <I>provided, however,</I> that the provisions of Section&nbsp;10 and Section&nbsp;11 shall at all times be effective and shall survive such
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14. No Advisory or Fiduciary Relationship. </B>The Company acknowledges and agrees that
(a)&nbsp;the purchase and sale of the Offered Securities pursuant to this Agreement, including the determination of the public offering price of the Offered Securities and any related discounts and commissions, is an
<FONT STYLE="white-space:nowrap">arm&#8217;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process
leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its shareholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will
assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on
other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be
engaged in a broad range of transactions that involve interests that differ from those of the Company, (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and
the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate, and (f)&nbsp;none of the activities of the Underwriters in connection with the transaction contemplated herein constitutes a
recommendation, investment advice, or solicitation of any action by the Underwriters with respect to any entity or natural person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15. Representations and Indemnities to Survive Delivery</B><B><I>.</I></B> The respective indemnities,
agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made
by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for
the Offered Securities sold hereunder and any termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16. Notices.</B> All communications hereunder shall be in
writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">If to the Representatives:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jefferies LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">520 Madison Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (646) <FONT STYLE="white-space:nowrap">619-4437</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Leerink Partners LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1301 Avenue of the Americas, 5th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Stuart R. Nayman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wells Fargo Securities, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">500 West 33rd Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10001</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (212) <FONT STYLE="white-space:nowrap">214-5918</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Equity Syndicate Department</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">with a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cooley LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">55 Hudson Yards</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10001</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Email:<U> dgoldberg@cooley.com</U> and <U>eleitner@cooley.com</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Daniel I. Goldberg and Evan Leitner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">If to the Company:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">enGene Holdings, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">c/o enGene USA, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">99 High Street, 26<SUP STYLE="font-size:75%; vertical-align:top">th </SUP>Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston, MA 02110</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Ryan Daws, Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Email: [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">with a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">enGene Holdings Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">c/o enGene USA, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">99 High Street, 26<SUP STYLE="font-size:75%; vertical-align:top">th </SUP>Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston, MA 02110</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Lee Giguere, Esq., Chief Legal Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Morgan, Lewis&nbsp;&amp; Bockius LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">One Federal Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston, MA 02110</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Julio E. Vega, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT> julio.vega@morganlewis.com</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the
others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17. Successors</B><B><I>.</I></B> This Agreement will inure to the benefit of and be binding upon
the parties hereto, including any substitute Underwriters pursuant to Section&nbsp;12 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section&nbsp;10 and Section&nbsp;11,
and in each case their respective successors, and personal representatives, and no other person will have any right or obligation hereunder. The term &#8220;<B>successors</B>&#8221; shall not include any purchaser of the Offered Securities as such
from any of the Underwriters merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;18. Partial Unenforceability.</B> The
invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is
for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.<B><I> </I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;19. Recognition of the U.S. Special Resolution Regimes.&#8195; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and
any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>In the event
that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are
permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, (A) &#8220;<B>BHC Act Affiliate</B>&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#8220;<B>Covered Entity</B>&#8221; means any of the following: (i)&nbsp;a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12
C.F.R. &#167; 382.2(b); (C) &#8220;<B>Default Right</B>&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#8220;<B>U.S. Special
Resolution Regime</B>&#8221; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;20. Governing Law Provisions</B><B><I>.</I></B> This Agreement shall be governed by and
construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions
contemplated hereby (&#8220;<B>Related Proceedings</B>&#8221;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case
located in the Borough of Manhattan in the City of New York (collectively, the &#8220;<B>Specified Courts</B>&#8221;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement
of a judgment of any such court (a &#8220;<B>Related Judgment</B>&#8221;), as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process,
summons, notice or document by mail to such party&#8217;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection
to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such
court has been brought in an inconvenient forum. The Company irrevocably appoints enGene USA, Inc., which currently maintains an address at 99 High Street, 26th Floor, Boston, MA 02110, as its agent to receive service of process or other legal
summons for purposes of any such suit, action or proceeding that may be instituted in any New York Court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any Related
Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity (whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and
execution to which it might otherwise be entitled in the Specified Courts, and with respect to any Related Judgment, each party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or
claim or cause to be pleaded any such immunity at or in respect of any such Related Proceeding or Related Judgment, including, without limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;21. Payments.</B> All payments made by the Company under this Agreement, if any, will be made without
withholdings or deduction for or on account of any present or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes on net income) imposed or levied by or on behalf of Canada or any political subdivision or
any taxing authority thereof or therein unless the Company is or becomes required by law to withhold or deduct such taxes, duties, assessments or other governmental charges. In such event, the Company will pay such additional amount as will result,
after such withholding or deduction, in the receipt by the Underwriters of the amount that would otherwise have been receivable in respect thereof had such withholding or deduction not been made, provided any such additional amount is payable in
respect of services performed by or on behalf of the Underwriters wholly outside of Canada and services performed in the ordinary course of business carried on by the Underwriters that include the performance of such services for a fee and the
Underwriters deal at arm&#8217;s length with the Company within the meaning of the Income Tax Act (Canada). For greater certainty, no additional amounts shall be paid by the Company if such deduction or withholding results from the performance of
services in Canada, the Underwriters carrying on business in Canada or the Underwriters being resident in Canada for purposes of the Income Tax Act (Canada). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;22. Judgment Currency.</B> If for the purposes of obtaining judgment in any court it is necessary to convert a
sum due hereunder into any currency other than United States dollars, the parties hereto agree, to the fullest extent permitted by law, that the rate of exchange used shall be the rate at which in accordance with normal banking procedures the
Underwriters could purchase United States dollars with such other currency in The City of New York on the business day preceding that on which final judgment is given. The obligation of the Company with respect to any sum due from it to any
Underwriter or any person controlling any Underwriter shall, notwithstanding any judgment in a currency other than United States dollars, not be discharged until the first business day following receipt by such Underwriter or controlling person of
any sum in such other currency, and only to the extent that such Underwriter or controlling person may in accordance with normal banking procedures purchase United States dollars with such other currency. If the United States dollars so purchased
are less than the sum originally due to such Underwriter or controlling person hereunder, the Company agrees as a separate obligation and notwithstanding any such judgment, to indemnify such Underwriter or controlling person against such loss. If
the United States dollars so purchased are greater than the sum originally due to such Underwriter or controlling person hereunder, such Underwriter or controlling person agrees to pay to the Company an amount equal to the excess of the dollars so
purchased over the sum originally due to such Underwriter or controlling person hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;23. General Provisions.</B> This Agreement constitutes the
entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in any
number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature
covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be
deemed to have been duly and validly delivered and be valid and effective for all purposes. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived
unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during
negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section&nbsp;10 and the contribution provisions of Section&nbsp;11, and is fully informed regarding said provisions. Each of the parties
hereto further acknowledges that the provisions of Section&nbsp;10 and Section&nbsp;11 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate
disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities Act and the Exchange Act.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company and the Custodian the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman"><B>ENGENE HOLDINGS INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Ryan Daws</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Ryan Daws</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: CFO</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representative[s] in New
York, New York as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acting individually and as Representative of the several Underwriters named in the attached <U>Schedule A.</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to Underwriting Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"><B>ENGENE HOLDINGS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New
York, New York as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>JEFFERIES LLC</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>LEERINK
PARTNERS LLC</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman"><B>WELLS FARGO SECURITIES, LLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acting individually and as Representatives of the several Underwriters named in the attached <U>Schedule A.</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>JEFFERIES LLC</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Matthew Kim</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Matthew Kim</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>LEERINK PARTNERS LLC</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>WELLS FARGO SECURITIES, LLC</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"><B>ENGENE HOLDINGS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New
York, New York as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>JEFFERIES LLC</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>LEERINK
PARTNERS LLC</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman"><B>WELLS FARGO SECURITIES, LLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acting individually and as Representatives of the several Underwriters named in the attached <U>Schedule A.</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"><B>LEERINK PARTNERS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Sean Pitt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Sean Pitt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Senior Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"><B>WELLS FARGO SECURITIES, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"><B>ENGENE HOLDINGS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New
York, New York as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>JEFFERIES LLC</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>LEERINK
PARTNERS LLC</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman"><B>WELLS FARGO SECURITIES, LLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acting individually and as Representatives of the several Underwriters named in the attached <U>Schedule A</U>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>JEFFERIES LLC</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>LEERINK PARTNERS LLC</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>WELLS FARGO SECURITIES, LLC</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Carolyn Hurley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Carolyn Hurley</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Managing Director</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number of<BR>Firm Shares<BR>to&nbsp;be&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of Pre-<BR>Funded&nbsp;Warrants</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,897,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,066,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">930,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,821,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">396,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raymond James&nbsp;&amp; Associates, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">627,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Van Lanschot Kempen (USA) Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">627,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">313,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,558,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,735,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pricing Information Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Price per share to the public:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Price per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to the public:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.4999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares being sold by the Company:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,558,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants being sold by the
Company:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,735,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares potentially issuable pursuant to the option to purchase additional
shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,294,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are exercisable any time following issuance (without expiry),
subject to beneficial ownership limitations, at option of holder, by payment of the exercise price in cash or by cashless exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants shall not be exercisable if the holders ownership would exceed the initial beneficial ownership limit as set such holder. However, any holder may increase the initial beneficial ownership
percentage, not to exceed 19.99%, if holder provides at least 61 days&#8217; notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the occurrence of a &#8220;Fundamental Transaction&#8221; (as
described in the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants) the holder of such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants shall be entitled to receive, upon exercise, the same kind and amount of securities, cash or
other property that such holders would have received had they exercised the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants immediately prior to such transaction, without regard to any limitations on exercise contained in the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. In the event the Holder does not exercise the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant as contemplated by the foregoing sentence, the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant shall be deemed exercised in full without regard to any limitations on exercise contained therein pursuant to the &#8220;cashless exercise&#8221; provision included therein upon the
effective date of the consummation of such Fundamental Transaction. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, if and to the extent not exercised or deemed exercised as provided above therein upon the effective date of the
consummation of a Fundamental Transaction, shall automatically terminate upon consummation of such Fundamental Transaction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Permitted Section&nbsp;5(d) Communications </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;12, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the Several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street, 40th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02109 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Wells Fargo Securities, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">375 Park Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10152 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">RE:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enGene Holdings Inc. (the &#8220;<B>Company</B>&#8221;) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies&nbsp;&amp; Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned is an owner of
common shares of the Company (&#8220;<B>Shares</B>&#8221;) or of securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public offering of Shares (the &#8220;<B>Offering</B>&#8221;) for which
Jefferies LLC, Leerink Partners LLC and Wells Fargo Securities, LLC (the &#8220;<B>Representatives</B>&#8221;) will act as the representatives of the underwriters. The undersigned recognizes that the Offering will benefit each of the Company and the
undersigned. The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering into an
underwriting agreement (the &#8220;<B>Underwriting Agreement</B>&#8221;) and other underwriting arrangements with the Company with respect to the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this agreement. Those definitions are a
part of this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the undersigned hereby agrees that, during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the undersigned will not (and will cause any Family Member not to), without the prior written consent of the Representatives, which
may withhold their consent in their sole discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or
beneficially (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by the undersigned or such Family Member, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EN-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any Swap, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the
offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly announce any intention to do any of the foregoing.&#8195; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing will not apply to the registration of the offer and sale of the Shares, and the sale of the Shares to the underwriters, in each case as
contemplated by the Underwriting Agreement. In addition, the foregoing restrictions shall not apply to the transfer of Shares or Related Securities by gift, or by will or intestate succession to a Family Member or to a trust whose beneficiaries
consist exclusively of one or more of the undersigned and/or a Family Member; <I>provided, however,</I> that in any such case, it shall be a condition to such transfer that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each transferee executes and delivers to the Representatives an agreement in form and substance satisfactory to
the Representatives stating that such transferee is receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities, engage
in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter agreement (as if such transferee had been an original signatory hereto), and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, no public disclosure or
filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial ownership of Shares in connection with such transfer.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#8217;s transfer agent and
registrar against the transfer of Shares or Related Securities held by the undersigned and the undersigned&#8217;s Family Members, if any, except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of
any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to
or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares. The undersigned will not, and will cause any Family Member not to take,
directly or indirectly, any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the underwriters have not provided any recommendation or investment
advice nor have the underwriters solicited any action from the undersigned with respect to the Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EN-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not the Offering occurs as currently contemplated or at all depends on market conditions and
other factors. The Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this letter agreement. This letter
agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EN-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000;">Printed Name of Person Signing</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>(Indicate capacity of person signing if signing as custodian or trustee, or on behalf of an entity)</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EN-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Defined Terms </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Used in <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the letter agreement to which this Annex A is attached and of which it is made a part: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#8220;Call</B><B> Equivalent Position&#8221; </B>shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#8220;Exchange</B><B> Act&#8221; </B>shall mean the Securities Exchange Act of 1934, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#8220;Family Member&#8221;</B> shall mean the spouse of the undersigned, an immediate family member of the
undersigned or an immediate family member of the undersigned&#8217;s spouse, in each case living in the undersigned&#8217;s household or whose principal residence is the undersigned&#8217;s household (regardless of whether such spouse or family
member may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise). <B>&#8220;Immediate</B><B> family member&#8221;</B> as used above shall have the
meaning set forth in Rule <FONT STYLE="white-space:nowrap">16a-1(e)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">&#8220;Lock-up</FONT></B><B> Period&#8221;</B> shall mean the period
beginning on the date hereof and continuing through the close of trading on the date that is 90 days after the date of the Prospectus (as defined in the Underwriting Agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#8220;Put Equivalent Position&#8221;</B> shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#8220;Related Securities&#8221;</B> shall mean any options or warrants or other rights to acquire Shares or
any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#8220;Securities Act&#8221;</B> shall mean the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#8220;Sell</B><B> or Offer to Sell&#8221;</B> shall mean to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, offer to sell, contract to sell or lend, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call
Equivalent Position </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pledge, hypothecate or grant any security interest in, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other way transfer or dispose of, in each case whether effected directly or indirectly.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#8220;Swap&#8221;</B> shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole
or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EN-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Directors, Officers and Others </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Signing <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Richard Glickman, LLD </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philip Astley-Sparke </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gerry Brunk, MBA </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">William Grossman, MD, PhD </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paul Hastings </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Heffernan, RPh </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wouter Joustra, MSc </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lota S. Zoth, CPA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Officers: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Executive Officers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ronald H.W. Cooper</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer, President and Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Matthew Boyd</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Regulatory Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jill Buck</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Development Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dr.&nbsp;Anthony&nbsp;T. Cheung</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Scientific Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joan Connolly</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Technology Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ryan Daws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lee G. Giguere</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Legal Officer and Corporate Secretary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dr.&nbsp;Alexander Nichols</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Strategy and Operations Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amy Pott</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Global Commercialization Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dr.&nbsp;Hussein Sweiti</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Medical Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Others: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forbion Growth </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lumira Ventures III, L.P. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forbion Capital Fund III Cooperatief
U.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EN-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d876714dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [&#149;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(subject
to adjustment) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Original&nbsp;Issue&nbsp;Date:&nbsp;[&#149;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant No. [&#149;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc., a corporation
continued under the <I>Business Corporations Act</I> (British Columbia) (the &#8220;<I>Company</I>&#8221;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [&#149;] or its
registered assigns (the &#8220;<I>Holder</I>&#8221;), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [&#149;] common shares (the &#8220;<I>Common Shares</I>&#8221;), of the Company (each such share,
a &#8220;<I>Warrant Share</I>&#8221; and all such shares, the &#8220;<I>Warrant Shares</I>&#8221;) at an exercise price per share equal to $0.0001 per share (the &#8220;<I>Exercise Price</I>&#8221;), upon surrender of this <I><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT></I> <I>Warrant to Purchase Common Shares </I>(including any <I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT></I> <I>Warrants to Purchase Common Shares </I>issued in exchange, transfer or replacement
hereof, the &#8220;<I>Warrant</I>&#8221;) at any time and from time to time on or after the date hereof (the &#8220;<I>Original Issue Date</I>&#8221;), subject to the following terms and conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. For purposes of this Warrant, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) &#8220;Affiliate&#8221; means any Person directly or indirectly controlled by, controlling or under common control with, the Holder, but only for so long
as such control shall continue. For purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, &#8220;controlled by&#8221;, &#8220;controlling&#8221; and &#8220;under common control with&#8221;) means, with respect to
a Person, possession, direct or indirect, of (a)&nbsp;the power to direct or cause direction of the management and policies of such Person (whether through ownership of securities or partnership or other ownership interests, by contract or
otherwise), or (b)&nbsp;at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) &#8220;<I>Commission</I>&#8221; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) &#8220;<I>Closing Sale Price</I>&#8221; means, for any security as of any date, the last trade price for such security on the Principal Trading Market for
such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M.,
New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on
the electronic bulletin board for such security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on
such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its
good faith judgment to determine the fair market value. The Board of Directors&#8217; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any share dividend, share
split, share combination or other similar transaction during the applicable calculation period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) &#8220;<I>Exchange Act</I>&#8221; means the United
States Securities Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) &#8220;<I>Principal Trading Market</I>&#8221; means the national securities exchange or other
trading market on which the Common Shares are primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) &#8220;<I>Prospectus</I>&#8221; means the prospectus supplement dated November [&#149;], 2025 of the Company, including the accompanying base prospectus
dated November&nbsp;21, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) &#8220;<I>Registration Statement</I>&#8221; means the Shelf Registration Statement, as of its most recent effective
date on or prior to the Original Issuance Date, including all documents and information filed as a part thereof or incorporated therein by reference and all documents and information deemed at such time to be included in the part of the Shelf
Registration Statement relating to this Warrant and the other Related Warrants (as defined in Section&nbsp;15(d)) pursuant to Rule&nbsp;430B(f)(2) under the Securities Act, including, without limitation, the Prospectus<I>.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) &#8220;<I>Related Warrants</I>&#8221; means, collectively, all of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Common Shares sold and issued by the Company pursuant to the Registration Statement, in each case as such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may be
exchanged, transferred or replaced from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) &#8220;<I>Securities Act</I>&#8221; means the United States Securities Act of 1933, as amended.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) &#8220;<I>Shelf</I> <I>Registration Statement</I>&#8221; means the Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-283201)</FONT> filed by the Company with the Commission pursuant to the Securities Act on November&nbsp;13, 2024 and declared effective on November&nbsp;21, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(j) &#8220;<I>Trading Day</I>&#8221; means any weekday on which the Principal Trading Market is normally open for trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(k) &#8220;<I>Transfer Agent</I>&#8221; means Continental Stock Transfer&nbsp;&amp; Trust Company, the Company&#8217;s transfer agent and registrar for the
Common Shares, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Sale and Issuance of Warrant;</U> <U>Warrant Register</U>. The Warrant, as initially
issued by the Company, is offered and sold pursuant to the Registration Statement. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<I>Warrant Register</I>&#8221;), in
the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of
this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Registration of Transfers</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole
or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or
attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any
portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Shares in substantially the form of
this Warrant (any such new warrant, a &#8220;<I>New Warrant</I>&#8221;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred,
if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has
in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#8217;s own expense any New Warrant under this <U>Section</U><U></U><U>&nbsp;3</U>. Until due presentment for registration
of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Exercise and Duration of Warrants</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) All or any
part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from time to time on or after the Original Issue Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company (i)&nbsp;an exercise notice, in the form attached as <U>Schedule 1</U> hereto (the
&#8220;<I>Exercise Notice</I>&#8221;), completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (unless the exercise takes the form of a &#8220;cashless
exercise&#8221; as required pursuant to Section&nbsp;10 below and/or if so indicated in the Exercise Notice pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below), and the date on which the last of such items is delivered to the Company (as
determined in accordance with the notice provisions hereof) is an &#8220;<I>Exercise Date</I>.&#8221; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise
Notice shall have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. The aggregate exercise price
for this Warrant, except for the Exercise Price, was <FONT STYLE="white-space:nowrap">pre-funded</FONT> to the Company on or before the Original Issue Date, and consequently no additional consideration (other than the Exercise Price) shall be
required by to be paid by the Holder to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> exercise price under any
circumstance or for any reason whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Delivery of Warrant Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than one (1)&nbsp;Trading Day after the Exercise Date), upon the request
of the Holder, credit such aggregate number of Common Shares to which the Holder is entitled pursuant to such exercise to the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company (&#8220;<I>DTC</I>&#8221;) through
its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program (the &#8220;<I>FAST Program</I>&#8221;) or if such aggregate number of Common Shares are required to bear
or be subject to a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a written notice of book-entry registration evidencing that the number of Common Shares
to which the Holder is entitled pursuant to such exercise has been registered in the Company&#8217;s share register in the name of the Holder or its designee (such written notice, a &#8220;<I>Notice of Book-Entry Registration</I>&#8221;). The
Holder, or any natural person or legal entity (each, a &#8220;<I>Person</I>&#8221;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date,
irrespective of the date such Warrant Shares are credited to the Holder&#8217;s DTC account or the date of delivery of the Notice of Book-Entry Registration evidencing such Warrant Shares, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) If by the close of the first (1st) Trading Day after the Exercise Date, the Company fails to deliver to the Holder the required number of Warrant Shares
in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> or fails to credit the Holder&#8217;s balance account with DTC for such number of Warrant Shares to which the Holder is entitled, and if after such first (1st) Trading Day and
prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) Common Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &#8220;<I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I>&#8221;), then the Company shall, within three (3)&nbsp;Trading Days after the Holder&#8217;s request and in the Holder&#8217;s sole discretion, promptly honor its obligation to
issue such Warrant Shares to the Holder and pay cash to the Holder in an amount equal to the excess (if any) of Holder&#8217;s total purchase price (including brokerage commissions, if any) for the Common Shares so purchased in the <FONT
STYLE="white-space:nowrap">Buy-In</FONT> over the product of (A)&nbsp;the number of Common Shares purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> times (B)&nbsp;the Closing Sale Price of a Common Share on the Exercise Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to Section&nbsp;5(b), the Company&#8217;s obligations to issue and deliver Warrant Shares in accordance with
and subject to the terms hereof (including the limitations set forth in <U>Section</U><U></U><U>&nbsp;11</U> below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with
respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person
of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with
the issuance of Warrant Shares. Subject to Section&nbsp;5(b), nothing herein shall limit the Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&#8217;s failure to timely issue the requisite Warrant Shares upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares upon exercise of this Warrant shall be made without charge to the Holder for any issue or
transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; <I>provided, however</I>, that
the Company shall not be required to pay any tax that may be payable in respect of any transfer of Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax
liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Replacement of Warrant</U>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft
or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and
procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition
precedent to the Company&#8217;s obligation to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Reservation of Warrant Shares</U>. The Company covenants that it will, at all
times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Shares, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this
Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder
(taking into account the adjustments and restrictions of <U>Section</U><U></U><U>&nbsp;9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in
accordance with the terms hereof, be duly and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such Common
Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Shares may be listed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>Certain Adjustments</U>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to
time as set forth in this <U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>Share Dividends and Splits</U>. If the Company, at any time while this Warrant is
outstanding, (i)&nbsp;pays a share dividend on its Common Shares that is payable in Common Shares, (ii)&nbsp;subdivides its outstanding Common Shares into a larger number of Common Shares, (iii)&nbsp;combines its outstanding Common Shares into a
smaller number of Common Shares or (iv)&nbsp;issues by reclassification of Common Shares any additional Common Shares of the Company, then in each such case the number of Warrant Shares for which this Warrant is then exercisable shall be multiplied
by a fraction, the numerator of which shall be the number of Common Shares outstanding immediately before such event and the denominator of which shall be the number of Common Shares outstanding immediately after such event. Any adjustment made
pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have
been fixed and such dividend is not fully paid on the date fixed therefor, the number of Warrant Shares for which this Warrant shall be exercisable shall be recomputed accordingly as of the close of business on such record date and thereafter the
number of Warrant Shares for which this Warrant shall be exercisable shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii)&nbsp;of this paragraph shall
become effective immediately after the effective date of such subdivision or combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If the Company, at any time
while this Warrant is outstanding, distributes to all holders of Common Shares for no consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of Common Shares covered by the preceding paragraph) or
(iii)&nbsp;rights or warrants to subscribe for or purchase any security, or (iv)&nbsp;cash or any other asset (in each case, &#8220;<I>Distributed Property</I>&#8221;), then, upon any exercise of this Warrant that occurs after the record date fixed
for determination of shareholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder
would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date without regard to any limitation on exercise contained therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company
effects any merger, amalgamation, arrangement or consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the shareholders of the Company immediately prior to such merger, amalgamation,
arrangement or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or
substantially all of its assets in one transaction or a series of related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of Common Shares tender shares representing more
than 50% of the voting power of the Common Shares of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the Common
Shares of the Company (except for any such transaction in which the shareholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the
transaction), provided, however, the foregoing shall not include transactions for which the primary purpose is raising capital and do not provide for any Alternate Consideration (as defined below) to be paid, distributed or made available to the
shareholders of the Company or (v)&nbsp;the Company effects any reclassification of the Common Shares or any compulsory share exchange pursuant to which the Common Shares are effectively converted into or exchanged for other securities, cash or
property (other than as a result of a subdivision or combination of Common Shares covered by <U>Section</U><U></U><U>&nbsp;9(a)</U> above) (in any such case, a &#8220;<I>Fundamental Transaction</I>&#8221;), then following such Fundamental
Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction (the
&#8220;<I>Alternate Consideration</I>&#8221;) if it had been, immediately prior to such Fundamental Transaction, the Holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on
exercise contained herein. In the event the Holder does not exercise this Warrant as contemplated by the foregoing sentence, this Warrant shall be deemed exercised in full without regard to any limitations on exercise contained herein pursuant to
the &#8220;cashless exercise&#8221; provision in Section&nbsp;10 hereof upon the effective date of the consummation of such Fundamental Transaction. The Company shall not effect any Fundamental Transaction in which the Company is not the surviving
entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the simultaneous &#8220;cashless exercise&#8221; of this Warrant pursuant to
<U>S</U><U>ection</U><U></U><U>&nbsp;10</U> below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume
the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph
(c)&nbsp;shall similarly apply to subsequent transactions analogous to a Fundamental Transaction type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Calculations</U>. All calculations under
this <U>Section</U><U></U><U>&nbsp;9</U> shall be made to the nearest <FONT STYLE="white-space:nowrap">one-tenth</FONT> of one cent or the nearest share, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this <U>Section</U><U></U><U>&nbsp;9</U>, the Company at its expense
will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price
and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is
based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Transfer Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares
a dividend or any other distribution of cash, securities or other property in respect of its Common Shares, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital of the Company or any subsidiary,
(ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits shareholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company,
then the Company shall deliver to the Holder a notice of such transaction at least ten (10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Shares in order to participate in or vote with respect
to such transaction; <I>provided, however</I>, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is
outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits shareholder approval for any Fundamental Transaction contemplated by <U>Section</U><U></U><U>&nbsp;9(c)</U>, other than a Fundamental Transaction
under clause (iii)&nbsp;of Section&nbsp;9(c), the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is consummated. Holder agrees to maintain any
information disclosed pursuant to this Section&nbsp;9(f) in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in the Company&#8217;s securities following receipt any such
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>Payment of Exercise Price</U>. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion,
satisfy its obligation to pay the Exercise Price through a &#8220;cashless exercise&#8221;, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section&nbsp;3(a)(9) of
the Securities Act, as determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;X&#8221; equals the number of Warrant Shares to
be issued to the Holder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Y&#8221; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;A&#8221; equals the Closing Sale Price of the Common Shares (as reported by Bloomberg Financial Markets) as of the Trading Day on the date immediately
preceding the Exercise Date; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;B&#8221; equals the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a
&#8220;cashless exercise&#8221; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the
Commission continues to take the position that such treatment is proper at the time of such exercise). In the event that a registration statement registering the issuance of Warrant Shares is, for any reason, not effective at the time of exercise of
this Warrant, then the Warrant may only be exercised through a cashless exercise, as set forth in this Section&nbsp;10. If the Warrant Shares are issued in such a cashless exercise, the Company acknowledges and agrees that, in accordance with
Section&nbsp;3(a)(9) of the Securities Act, the Warrant Shares issued in such exercise shall take on the registered characteristics of the Warrants being exercised and may be tacked on to the holding period of the Warrants being exercised. Except as
set forth in Section&nbsp;5(b) <FONT STYLE="white-space:nowrap">(Buy-In</FONT> remedy) and Section&nbsp;12 (payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be settled in cash. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <U>Limitations on Exercise</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to
exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i)&nbsp;the aggregate number of Common Shares beneficially owned by the
Holder, its Affiliates and any Persons who are members of a Section&nbsp;13(d) group with such Holder or its Affiliates to exceed [4.99 / 9.99 / 19.99]% (the &#8220;<I>Maximum Percentage</I>&#8221;) of the total number of issued and outstanding
Common Shares of the Company following such exercise, or (ii)&nbsp;the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons who are members of a Section&nbsp;13(d) group
with such Holder or its Affiliates, to exceed the Maximum Percentage of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this paragraph, beneficial ownership and whether a
Holder is a member of a Section&nbsp;13(d) group shall be calculated and determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder. For purposes of this Warrant, in determining the number of
outstanding Common Shares, the Holder may rely on the number of outstanding Common Shares as reflected in (x)&nbsp;the Company&#8217;s most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed with the Commission prior to the date hereof, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other notice by the Company or the Transfer Agent setting forth
the number of Common Shares outstanding. Upon the written request of the Holder, the Company shall within three (3)&nbsp;Trading Days confirm in writing or by electronic mail to the Holder the number of Common Shares then outstanding. In any case,
the number of outstanding Common Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding Common Shares was
reported. In the event that the issuance of Common Shares to the Holder upon exercise of this Warrant results in the Holder, together with the Attribution Parties, being deemed to beneficially own, in the aggregate, more than the Maximum Percentage
of the number of outstanding Common Shares (as determined under Section&nbsp;13(d) of the Exchange Act), the number of shares so issued by which the Holder&#8217;s, together with the Attribution Parties&#8217;, aggregate beneficial ownership exceeds
the Maximum Percentage (the &#8220;<I>Excess Shares</I>&#8221;) shall be deemed null and void and shall be cancelled ab initio, and the Holder and/or the Attribution Parties shall not have the power to vote or to transfer the Excess Shares. As soon
as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. By written notice to the Company, the Holder may
from time to time increase or decrease the Maximum Percentage to any other percentage specified in such notice not in excess of 19.99%; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is
delivered to the Company. For purposes of this Section&nbsp;11(a), the aggregate number of Common Shares or voting securities beneficially owned by the Holder and its Affiliates and any other Persons who are members of a Section&nbsp;13(d) group
with such Holder or its Affiliates shall include the Common Shares issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Common Shares which would be issuable upon
(x)&nbsp;exercise of the remaining unexercised and <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of this Warrant by the Holder and (y)&nbsp;the exercise or conversion of the unexercised,
<FONT STYLE="white-space:nowrap">non-converted</FONT> or <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company
which would entitle the Holder thereof to acquire at any time Common Shares, including without limitation any debt, preferred shares, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for,
or otherwise entitles the Holder thereof to receive, Common Shares), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons
who are members of a Section&nbsp;13(d) group with such Holder or its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) This <U>Section</U><U></U><U>&nbsp;11</U> shall not restrict the
number of Common Shares which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in
<U>Section</U><U></U><U>&nbsp;9(c)</U> of this Warrant. For purposes of clarity, the Common Shares issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder or the
Attribution Parties for any purpose including for purposes of Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder or Section&nbsp;16 of the Exchange Act and the rules promulgated thereunder, including Rule <FONT
STYLE="white-space:nowrap">16a-1(a)(1).</FONT> No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of
exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this <U>Section</U><U></U><U>&nbsp;11</U> to the extent necessary to correct this paragraph or any
portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this <U>Section</U><U></U><U>&nbsp;11</U> or to make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <U>No Fractional Shares</U>. No fractional Warrant Shares will be issued in connection with any exercise
of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on
the Closing Sale Price) for any such fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <U>Notices</U>. Any and all notices or other communications or deliveries hereunder
(including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via facsimile or confirmed <FONT
STYLE="white-space:nowrap">e-mail</FONT> at the facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified in the books and records of the Company prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next
Trading Day after the date of transmission, if such notice or communication is delivered via facsimile or confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address
specified in the books and records of the Transfer Agent on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized
overnight courier service specifying next business day delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <U>Warrant Agent</U>. The Company shall initially serve as warrant agent under this Warrant. Upon thirty (30)&nbsp;days&#8217; notice to the Holder, the
Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any
corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant
agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#8217;s last address as shown on the Warrant Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a
Shareholder</U>. The Holder, solely in such Person&#8217;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained
in this Warrant be construed to confer upon the Holder, solely in such Person&#8217;s capacity as the Holder of this Warrant, any of the rights of a shareholder of the Company or any right to vote, give or withhold consent to any corporate action
(whether any reorganization, issue of shares, reclassification of shares, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the
Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities
(upon exercise of this Warrant or otherwise) or as a shareholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. (i)&nbsp;Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including,
without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder
as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to
such increase in par value, (b)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the
exercise of this Warrant, and (c)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its
obligations under this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) Before taking any action which would result in an adjustment in the number of Warrant Shares for which
this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be
assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective
successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This
Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as
otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of
the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS
WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE
JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING
WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH
OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH
EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY
RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g)
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and
enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a
commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ENGENE HOLDINGS INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ryan Daws</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to
enGene Holdings <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SCHEDULE 1 </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF EXERCISE NOTICE </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be
executed by the Holder to purchase Common Shares under the Warrant] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of Warrant No. __ (the &#8220;<I>Warrant</I>&#8221;) issued by enGene Holdings Inc., a corporation continued under the
<I>Business Corporations Act</I> (British Columbia) (the &#8220;<I>Company</I>&#8221;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The undersigned hereby exercises its right to purchase Warrant Shares pursuant to the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price shall be made as (check one): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash Exercise </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Cashless Exercise&#8221; under Section&nbsp;10 of the Warrant </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $___________ in immediately available funds to the Company in accordance with
the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the
terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the
exercise evidenced hereby the Holder will not beneficially own in excess of the number of Common Shares (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under
<U>Section</U><U></U><U>&nbsp;11(a)</U> of the Warrant to which this notice relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name&nbsp;of&nbsp;Holder:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d876714dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g876714g36g59.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g876714g68a77.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g876714g69i42.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;14, 2025</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4868 Rue Levy, Suite 220</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Saint-Laurent, QC, Canada H4R 2P1</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Re:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Offering of 12,558,823 Common Shares and 2,735,295
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants of enGene Holdings Inc.</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs/Mesdames: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
acted as Canadian counsel to enGene Holdings Inc. (the &#8220;<B>Company</B>&#8221;), a company existing under the laws of British Columbia, in connection with the offer and sale (the &#8220;<B>Offering</B>&#8221;) by the Company of: (i) 12,558,823
common shares in the capital of the Company (the &#8220;<B>Common Shares</B>&#8221;), and up to 2,294,117 additional Common Shares issuable upon exercise of an option (the &#8220;<B>Over-Allotment Option</B>&#8221;) to purchase additional Common
Shares granted to the Underwriters (as defined below) (collectively, the &#8220;<B>Offered Shares</B>&#8221;); and (ii) 2,735,295 <FONT STYLE="white-space:nowrap">pre-funded</FONT> Common Share purchase warrants of the Company (the &#8220;<B><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</B>&#8221;), pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-283201)</FONT> (the
&#8220;<B>Registration Statement</B>&#8221;), filed by the Company on November&nbsp;13, 2024, as amended, with the Securities and Exchange Commission (the &#8220;<B>SEC</B>&#8221;) under the Securities Act of 1933, as amended (the
&#8220;<B>Securities Act</B>&#8221;), the prospectus included in the Registration Statement (the &#8220;<B>Base Prospectus</B>&#8221;), and the prospectus supplement related to the Offered Shares filed by the Company on November&nbsp;12, 2025 with
the SEC pursuant to Rule 424(b)(5) promulgated under the Securities Act (together with the Base Prospectus, the &#8220;<B>Prospectus</B>&#8221;). Reference in this opinion to Offered Shares shall include Offered Shares that comprise the
Over-Allotment Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering is being made pursuant to the terms of an underwriting agreement dated November&nbsp;12, 2025 (the
&#8220;<B>Underwriting Agreement</B>&#8221;) by and between the Company and Jefferies LLC, Leerink Partners LLC, and Wells Fargo Securities, LLC, on their own behalf and for the several underwriters listed in Schedule &#8220;A&#8221; thereto
(collectively, the &#8220;<B>Underwriters</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant is exercisable by the holder
thereof at any time following the date of issuance in accordance with its terms for one common share of the Company (a &#8220;<B>Warrant Share</B>&#8221;) at a nominal exercise price of US$0.0001 per Warrant Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with giving this opinion, we have examined the Registration Statement (including exhibits thereto) and the Prospectus. We have also examined and
considered originally executed copies, certified copies, photostatic copies and/or electronically transmitted copies of each of the following documents (collectively, the &#8220;<B>Documents</B>&#8221;): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company&#8217;s articles and notice of articles; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certificate of good standing dated November&nbsp;13, 2025 issued by the British Columbia Registrar of
Companies pursuant to the <I>Business Corporations Act</I> (British Columbia) relating to the Company (the &#8220;<B>Certificate of Good Standing</B>&#8221;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Underwriting Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the form of certificate representing the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g876714g10a40.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g876714g36g59.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g876714g68a77.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g876714g69i42.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the form of certificate representing the Offered Shares and Warrant Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such other documents, statutes, regulations, and public and corporate records as we have deemed appropriate to
give this opinion. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have relied upon the factual matters contained in the representations and other factual statements of the Company
made in the Documents and upon certificates of public officials and the officers of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In giving this opinion, we have assumed: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents
submitted to us as originals, the conformity to original documents of all documents submitted to us as duplicates or certified or conformed copies, and the authenticity of the originals of all such latter documents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the covenants, acknowledgements, representations and warranties of each of the parties to the Documents
are true and accurate in all material respects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent a party to any of the Documents has executed or delivered each of the Documents to which it is a
party outside the Province of British Columbia, such party has done so in compliance with the formal requirements of the laws of the jurisdiction in which such document has been executed; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that each of the parties (other than the Company) executing any of the Documents has, to the extent applicable,
duly and validly executed and delivered each of the Documents to which such party is a signatory and such parties had the capacity to do so and to perform their obligations thereunder, and such Documents or agreements constitute legal, valid and
binding obligations of all parties thereto and are enforceable in accordance with their respective terms against all parties thereto. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions expressed herein are limited to matters governed by the laws of the Province of British Columbia and the laws of Canada applicable therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In giving the opinion in paragraph 1 we have relied solely upon the Certificate of Good Standing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based and relying upon and subject to the foregoing, we are of the opinion that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is validly existing as a corporation in good standing with respect to the filing of annual reports
under the <I>Business Corporations Act</I> (British Columbia). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Offered Shares to be issued and sold by the Company have been duly authorized by the Company and, when the
Offered Shares are issued and paid for in accordance with the terms of the Underwriting Agreement, the Offered Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares in the capital of the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been duly and validly authorized, executed
and delivered by the Company (to the extent that execution and delivery are governed by the laws of British Columbia). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to be issued and sold by the Company, when
issued and paid for in accordance with the terms of the Underwriting Agreement, will be validly created and issued securities of the Company and, upon receipt by the Company of the payment or satisfaction of the exercise price for the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in accordance with the terms thereof, the Warrant Shares will be validly issued by the Company as fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares in the capital of
the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g876714g10a40.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g876714g36g59.jpg" ALT="LOGO" STYLE="width:8.85833in;height:0.38125in;">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g876714g68a77.jpg" ALT="LOGO" STYLE="width:2.24097in;height:0.795139in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g876714g69i42.jpg" ALT="LOGO" STYLE="width:2.125in;height:1.21944in;">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the reference to our firm under the caption &#8220;<I>Legal Matters</I>&#8221; in the
Prospectus and to the filing of this opinion letter as an exhibit to the Prospectus for incorporation by reference into the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
opinion is effective as at the date hereof and is based upon laws in effect and facts in existence as at the date hereof. We express no opinion as to the effect of future laws or judicial decisions on the subject matter hereof, nor do we undertake
any duty to modify this opinion to reflect subsequent facts or developments concerning the Company or developments in the law occurring after the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours truly, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Blake, Cassels&nbsp;&amp; Graydon LLP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g876714g10a40.jpg" ALT="LOGO" STYLE="width:5.47569in;height:0.360417in;">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>5
<FILENAME>d876714dex52.htm
<DESCRIPTION>EX-5.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan, Lewis&nbsp;&amp; Bockius&nbsp;<SMALL>LLP</SMALL> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One
Federal Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts <FONT STYLE="white-space:nowrap">02110-1726</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel. +1.617.341.7700 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax: +1.617.341.7701 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">www.morganlewis.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4868 Rue Levy, Suite 220 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Saint-Laurent, QC, Canada H4R 2P1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;14, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as United States federal and State of New York counsel to enGene Holdings Inc., a corporation incorporated under the laws of
British Columbia, Canada (the &#8220;<U>Company</U>&#8221;), in connection with the Company&#8217;s firm commitment, underwritten public offering (the &#8220;<U>Offering</U>&#8221;) of (i)&nbsp;an aggregate of 12,558,823 common shares, no par value,
of the Company (the &#8220;<U>Firm Shares</U>&#8221;), (ii) <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the &#8220;<U><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</U>&#8221;) to purchase up to 2,735,295 common shares
of the Company (the &#8220;<U>Warrant Shares</U>&#8221;), and (iii)&nbsp;solely for the purpose of covering over-allotments, up to an additional 2,294,117 common shares of the Company issuable upon exercise of an option granted to the underwriters
by the Company (the &#8220;<U>Optional Shares</U>&#8221; and, together with the Firm Shares and the Warrant Shares, the &#8220;<U>Shares</U>&#8221;). The Offering is being carried out pursuant to the terms and conditions set forth in the
Underwriting Agreement, dated November&nbsp;12, 2025 (the &#8220;<U>Underwriting Agreement</U>&#8221;), by and among the Company and Jefferies LLC, Leerink Partners LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters
named therein (the &#8220;<U>Underwriters</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You have requested that we furnish this opinion letter to you in connection with
the filing of a prospectus supplement, dated November&nbsp;12, 2025 (the &#8220;<U>Prospectus Supplement</U>&#8221;), with respect to the Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to be sold pursuant to the Offering. In
connection with this opinion letter, we have examined originals, or copies certified or otherwise identified to our satisfaction, of (i)&nbsp;the Underwriting Agreement, (ii)&nbsp;the Registration Statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-283201)</FONT> (the &#8220;<U>Registration Statement</U>&#8221;) filed by the Company with the Securities and Exchange Commission (the
&#8220;<U>Commission</U>&#8221;) pursuant to the Securities Act of 1933, as amended (the &#8220;<U>Securities Act</U>&#8221;) on November&nbsp;13, 2024 and declared effective on November&nbsp;21, 2024, (iii) the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, and (iv)&nbsp;such other documents and records as we deemed appropriate for purposes of the opinions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of the documents submitted to us as
originals, the conformity to the original documents of all documents submitted to us as certified, facsimile or photostatic copies, and the authenticity of the originals of all documents submitted to us as copies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing and to the limitations, qualifications and assumptions described below, we are of the opinion that the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, when duly executed and delivered by the Company to the purchasers thereof against payment therefor pursuant to the Underwriting Agreement and the terms of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion expressed above is subject to the following limitations, exceptions,
qualifications and assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A. We have assumed that (i)&nbsp;the Company is a corporation duly organized, validly existing and in
good standing under the laws of British Columbia, Canada, (ii)&nbsp;the Company has the requisite power and authority under the laws of British Columbia, Canada to execute, deliver and perform its obligations under the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, (iii)&nbsp;the execution, delivery and performance by the Company of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been duly authorized by the Company under and in
accordance with the laws of British Columbia, Canada, (iv)&nbsp;the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been duly executed and delivered by the Company under and in accordance with the laws of the British Columbia,
Canada, and (v)&nbsp;the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants constitute a valid and binding obligation of the applicable holders thereof other than the Company.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">B. We have assumed without any independent investigation that the Company has received the consideration called for by the resolutions of the
Board of Directors or any committee thereof authorizing the issuance of the <FONT STYLE="white-space:nowrap">Pre-</FONT> Funded Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C. The enforcement of any obligations of the Company or any other person may be limited by bankruptcy, insolvency, reorganization, moratorium,
marshalling or other laws and rules of law affecting the enforcement generally of creditors&#8217; rights and remedies, including, without limitation, fraudulent conveyance and fraudulent transfer laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">D. Our opinion is subject to the effects of general principles of equity (whether considered in a proceeding at law or in equity), including
but not limited to principles limiting the availability of specific performance or injunctive relief, and concepts of materiality and reasonableness, and the implied duty of good faith and fair dealing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">E. We express no opinion as to the enforceability of any particular provision of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants relating to or constituting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">waivers of rights to object to jurisdiction or venue, consents to jurisdiction or venue, or waivers of rights
to (or methods of) service of process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">waivers of rights to trial by jury, or other rights or benefits bestowed by operation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">waivers of any applicable defenses, setoffs, recoupments, or counterclaims; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the grant of powers of attorney or proxies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">exculpation or exoneration clauses, clauses relating to indemnification or contribution, and clauses relating
to releases or waivers of unmatured claims or rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">submission to binding arbitration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the imposition or collection of interest on overdue interest or providing for a penalty rate of interest or
late charges on overdue or defaulted obligations, or the payment of any premium, liquidated damages, or other amount which may be held by any court to be a &#8220;penalty&#8221; or a &#8220;forfeiture&#8221;; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any provision agreeing not to plead, or waiving or extending, or having the effect of waiving or extending, any
applicable statute of limitations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we express no opinion as to noncontravention of financial covenants or other provisions
of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants requiring financial calculations or determinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are opining
solely on the laws of the State of New York. Our opinion is based on these laws as in effect on the date hereof, and we assume no obligation to revise or supplement this opinion should the law be changed by legislative action, judicial decision, or
otherwise. We express no opinion as to whether the laws of any other jurisdiction are applicable to the subject matter hereof. We are not rendering any opinion as to compliance with any other international, Federal or state law, rule or regulation
relating to securities, or to the sale or issuance thereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter is effective only as of the date hereof. We do not assume responsibility for
updating this letter as of any date subsequent to its date, and we assume no responsibility for advising you of any changes with respect to any matters described in this letter that may occur, or facts that may come to our attention, subsequent to
the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter is furnished by us solely for filing as an exhibit to the Company&#8217;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed with the Commission on November&nbsp;14, 2025, and may not be used or relied for any other purpose whatsoever. We hereby consent to the filing of this opinion with the Commission as an exhibit to such
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (and its incorporation by reference into the Registration Statement) in accordance with the requirements of Item&nbsp;601(b)(5) of
<FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> promulgated under the Securities Act and to the reference to this firm therein and under the heading &#8220;Legal Matters&#8221; in the Prospectus Supplement that is part of the
Registration Statement. In giving this consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act, or the rules and regulations of the Commission thereunder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Morgan, Lewis &amp; Bockius LLP</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>d876714dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g876714g1113115900114.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>enGene Announces Pricing of $130 Million Public Offering of Common Shares and <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOSTON</B><B></B><B>&nbsp;&amp; MONTREAL &#8211; November</B><B></B><B>&nbsp;12, 2025
&#8211;</B> enGene Holdings Inc. (Nasdaq: ENGN, &#8220;enGene&#8221; or the &#8220;Company&#8221;), a clinical-stage, <FONT STYLE="white-space:nowrap">non-viral</FONT> genetic medicines company, today announced the pricing of its previously
announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 2,735,295 shares of its common shares at an offering price
of $8.4999 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, in each case, before underwriting discounts and commissions. The aggregate gross proceeds to enGene from the offering, before deducting the underwriting discounts and
commissions and offering expenses payable by enGene, are expected to be approximately $130&nbsp;million. All securities to be sold in the offering will be offered by enGene. In addition, enGene has granted to the underwriters a <FONT
STYLE="white-space:nowrap">30-day</FONT> option to purchase up to 2,294,117 additional common shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about November&nbsp;14, 2025,
subject to the satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies, Leerink Partners and Wells Fargo Securities are acting as joint book running
managers for the offering. Raymond James and Van Lanschot Kempen are acting as <FONT STYLE="white-space:nowrap">co-lead</FONT> managers for the offering. H.C. Wainwright&nbsp;&amp; Co. is acting as <FONT STYLE="white-space:nowrap">co-manager</FONT>
for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above are being offered by enGene pursuant to its effective shelf registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-283201)</FONT> filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on November&nbsp;13, 2024 and declared effective on
November&nbsp;21, 2024. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC&#8217;s website at http://www.sec.gov. When available, copies of the
final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone: (877) <FONT
STYLE="white-space:nowrap">821-7388,</FONT> or by emailing prospectus_department@jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor,&nbsp;Boston, MA&nbsp;02109, by telephone at (800) <FONT
STYLE="white-space:nowrap">808-7525,</FONT> ext. 6105, or by email at&nbsp;syndicate@leerink.com; or Wells Fargo Securities, LLC, 90 South 7th Street, 5th Floor,&nbsp;Minneapolis, MN&nbsp;55402, by telephone at (800)
<FONT STYLE="white-space:nowrap">645-3751</FONT> (option #5), or by email at&nbsp;WFScustomerservice@wellsfargo.com.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No securities are being offered or
sold, directly or indirectly, in Canada or to any resident of Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an
offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such
state or other jurisdiction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About enGene</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enGene is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with
the goal of creating new ways to address diseases with high clinical needs. enGene&#8217;s lead program is detalimogene voraplasmid (also known as detalimogene, and previously <FONT STYLE="white-space:nowrap">EG-70)</FONT> for patients with <FONT
STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying
detalimogene in high-risk, Bacillus <FONT STYLE="white-space:nowrap">Calmette-Gu&eacute;rin</FONT> (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using
enGene&#8217;s proprietary Dually Derivatized Oligochitosan<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including
DNA and various forms of RNA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements contained in this press release may constitute &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995, and &#8220;forward-looking information&#8221; within the meaning of Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;). enGene&#8217;s forward-looking statements
include, but are not limited to, statements regarding enGene&#8217;s management teams&#8217; expectations, hopes, beliefs, intentions, goals, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or
other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements, and they may also include statements express or implied, about enGene&#8217;s expectations regarding the offering,
including the timing, structure and completion of the offering on the anticipated size and terms, the grant to the underwriters of the option to purchase additional shares and the potential value and clinical benefit of enGene&#8217;s product
candidates. The words &#8220;anticipate&#8221;, &#8220;appear&#8221;, &#8220;approximate&#8221;, &#8220;believe&#8221;, &#8220;continue&#8221;, &#8220;could&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;foresee&#8221;,
&#8220;intends&#8221;, &#8220;may&#8221;, &#8220;might&#8221;, &#8220;plan&#8221;, &#8220;possible&#8221;, &#8220;potential&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;seek&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, and
similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many factors, risks, uncertainties, and assumptions could cause the Company&#8217;s actual results, performance, or achievements to differ materially from
those expressed or implied by the forward-looking statements, including, without limitation, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the offering, general economic conditions, , and
other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on EDGAR, including those described in the &#8220;Risk Factors&#8221; section of
the Company&#8217;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended October&nbsp;31, 2024 (copies of which may be obtained at www.sedarplus.ca or www.sec.gov). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not place undue reliance on any forward-looking statements, which speak only as of the date on
which they are made. enGene anticipates that subsequent events and developments will cause enGene&#8217;s assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically
disclaims any obligation to do so, unless required by applicable law. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the
contemplated results of such forward-looking statements will be achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For media contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>media@engene.com </U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For investor contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@engene.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>engn-20251112.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 75.0.3 -->
<!-- Creation date: 11/14/2025 3:59:45 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:engn="http://engene.com/20251112"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:us-types="http://fasb.org/us-types/2025"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://engene.com/20251112"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" namespace="http://fasb.org/us-types/2025" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="engn-20251112_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="engn-20251112_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="engn-20251112_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="engn_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="engn_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>engn-20251112_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='us-ascii'?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 75.0.3 -->
<!-- Creation date: 11/14/2025 3:59:51 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns='http://www.xbrl.org/2003/linkbase' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xsi:schemaLocation='http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd'>
  <link:arcroleRef xlink:type='simple' xlink:href='http://www.xbrl.org/2005/xbrldt-2005.xsd#all' arcroleURI='http://xbrl.org/int/dim/arcrole/all' />
  <link:arcroleRef xlink:type='simple' xlink:href='http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default' arcroleURI='http://xbrl.org/int/dim/arcrole/dimension-default' />
  <link:arcroleRef xlink:type='simple' xlink:href='http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain' arcroleURI='http://xbrl.org/int/dim/arcrole/dimension-domain' />
  <link:arcroleRef xlink:type='simple' xlink:href='http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member' arcroleURI='http://xbrl.org/int/dim/arcrole/domain-member' />
  <link:arcroleRef xlink:type='simple' xlink:href='http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension' arcroleURI='http://xbrl.org/int/dim/arcrole/hypercube-dimension' />
  <link:roleRef roleURI="http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="engn-20251112.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="engn-20251112.xsd#engn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="engn_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="engn-20251112.xsd#engn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="engn_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="engn_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="engn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0.01" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCountry" order="26.231" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.331" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="31.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.011" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="39.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="40.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="41.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="43.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="44.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="46.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="47.001" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>engn-20251112_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 75.0.3 -->
<!-- Creation date: 11/14/2025 3:59:39 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="engn-20251112.xsd#engn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="engn_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DocumentAndEntityInformationTable" xlink:to="engn_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="engn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="engn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="engn-20251112.xsd#engn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="engn_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="engn_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="engn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="engn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line 1</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line 1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>engn-20251112_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 75.0.3 -->
<!-- Creation date: 11/14/2025 3:59:34 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="engn-20251112.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="engn-20251112.xsd#engn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="engn_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="engn_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="engn-20251112.xsd#engn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="engn_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationTable" xlink:to="engn_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0.01" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCountry" order="26.231" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.331" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g876714g10a40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g876714g10a40.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  B @8# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * *FF:K:ZQ;O/9R^=$LLD!;:5P\;LCCD#HRL,]\<<4 6Z "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H AO+.#4+2>UNH([FUG1HI8)D#I(C##*RG@@@D$'K0!XE=? 6^M=*O+/2[
M;18?._M1K0HS0#39Y[IY+:[B"1G,L<)B3^$KY056VDF@8[3_ (&:MIMY-)<C
M2=>T^XOI+RXTFZ8P03EC<;3)MB(D9#)&0S@D^QB0D$03? GQ)<V]S:7>IV&I
MV5ZDTEU'>RRN#<?83;Q2@,I'+D,V>GE(PRQ- '1:%\)KS0?%MK>VUMI=M:P7
M<<L=W;R,DT-JMF(FLUC"!?+:8-+C<%RY;;O&2 >K4 % !0 4 % &-XRTJ]UW
MPEK.G:==?8K^[LY8(+C>R>6[(0IW+\R\GJO(ZCF@#S37_A=XJO)+4Z ="\+Z
M;:V$]FNBVAD\N4W"R+,QD1%"@'[/(/W;$M$1E=Q)!EG7O /C'4/%$VN6G]B1
M:@[%K>ZNI6G>PC^RM%Y,.Z'(!EQ*64H3O=6!"KD$8NB?L_ZS::_9R:GJ]I?Z
M98VPL(# )(IOL[&\+JI?S'CV?:8E4"4[UA&\\# ,]5\!:#>>&_".F66J77V_
M6!$)-1O VX3W3?-,XX'RERVT8 "X     (Z"@ H * "@ H \V\<>!O%6KZ_>
MSZ!J]KIME=6F4>9I/-MK[8\'GJH&&'DS%MNY?GMXQP&9E .?'PB\9(=+,?B*
MUMY+2V@TZ1H&E$<EO#-.\,P1MQ$J*T(P6(.Z4,QPIH ?=?!Z_FTL06NBZ#IE
MT;0Q07,%RY;3[S !OX_W(WS'"DD[6_=("WSM@ MZO\+_ !+J=KJ M]3@TR^2
M39I][%<2,R1O+="5V78,,(;L[5R1YD:Y( !H P+W]GB_E:Y%G)IMF@U":\A.
MR)F9,R^2FX6P=&59% D9Y&C.2A&,$&>]4""@ H * "@ H \._P"%-^,9+VX6
M;6;*72X#<FRMO/E#2)<3K/<13'9]URIC!&=B.< ]*!DD_P &O$2ZI->:9-IF
MC6,CV\2Z'%-(UK':B7=-&N(P%)(652%QN+Q\*Q>@0RV^ -UIFO\ AN^TX:5I
M]MI>IZA>RV]HODM*D^H1S0A7$65*0($(&-P7RL[&+ &0:7\$?%FD:)HUI9ZC
MI5K_ &?836LENN56YDGC,<TA>&&)1MQ$ZEHG9BI!89+$ ]HT&.\AT>TBU".&
M*[CC".MO,TJ<<9#,JDYZ]!0(OT % !0 4 % 'G_BOX>S^(O%JW\EEIM[;D6B
MI<W;'SK6-)6:XBC7805F0[&^9=P8AL@ 4 <TWP&_L^'2)=#M-"T?5K70[S3C
MJ,-J!)%=3-;B.Y3" LT:I<$$E3E\9 9B 9E7?P"\2SP1VT>O6UO;160LXEM7
MGB6/][)"9%4ESD6$SQ*&=L-&AW'[P /0/A]X0\0>&-;\0W.J:C9W=CJLPNXK
M6V20&UDW."NYB=X\KR$! 0?N?N?,30([J@ H * "@ H X[XB^#]1\5_V%+IE
M\+"[TJ]:^CE,C)\X@E1 0H.Y"SJ&4]4+=\4 >6:-^SWXCT[2$B?4-/&HNUM#
M<7,<O,ML;7[+<KO6W64L$>1T#R,N](^$Y(!GH?A_P+KL7PSO=(US4H;[Q-<B
M1VU&)FV>>N%MY1E<JRB.%CQPRG&>X(YS5/@OJ'DW<&G"R%U)$Z1:Y=7#F\56
MM#&\3'RR2KS,TK$-C,C-MW 9!AX'^#FO^$M8TZ635K>YTRSE(;3E8QP3(99W
M201JBK&\0EC"H,QDAR0&*,@(]DH * "@ H * ,/QUHMUXD\$^(=(L94@O;_3
MKBU@ED8JJ2/$RJQ(!( )!R 30!POBCX<:[XEOKV]>VTJ+4KA(EMM1-W(TNG(
MH(DAB/D@E)!G<<K_ *UL@[5W '+W'P)\4.WDM<Z7?P6NG7%CIL]U=S":R=TA
M$-PI\LD20E)%5@P8J%.X%FP ;FK_  <U75I;U5>RL);JY,ESJUM<.EW=I_:,
M%PA<B,8:*&)T3+, 6 &U2:!F[\%/!GB;P9I7B1/%=W87NH:EKMSJ4<NG2R-&
M8I%CQE74&,Y5CL!8 $?,:!'HM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M!/J=JJ/H!0 V+1K:,ZGN4S)J$GF3QRX*G]TD94#'0J@X.>IH Y<?!+X?BW6
M>#-#\E05$?V&/&"&!&,=,.PQZ,1TXH LI\)/!4;1LGA72$:.4S(RV: JY>1R
MP..I::8D]_-?^\<@ WPE\%LDZMX6TDB>?[5+FT3+R\?O"<<MA0,]< #IQ0 ^
M'X5>#;>2[DB\+:1%)=[_ +0Z6<8,N_[X8XY!]* -3P[X2T7PDE^FB:5::4E_
M=R7]VMI"L8GN'QOE? ^9VVC+'DX% &M0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g876714g1113115900114.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g876714g1113115900114.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  -$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"YN8+2$RSRK'&
M.K,<"IZR->TM]7T[[*L@CRX;<1GI3C9O4SJRG&#<%=E*Y\9:3 2$D>=A_P \
MUX_,UC77CR=^+6S1/]J1L_H*X_QE;S^'=3@LK:3SC)#YC,4YSDCBN<\G5[SE
MS(%/J=HKTJ6&IN/,?*8G,,<I.,Y*'H=I?>+]0D#"?41$I_A0A?\ Z],T7X@6
M6B)<F2.XO)I64K@X& #U)KE(_#[L<S3C_@(S75^%O#GAK9<W&LNA$)7;Y\VU
M3^'&:TJPI1AJC#!59SQ*:J7EKOL;7_"TT_Z!$G_?W_ZU%7O^+?\ ]_3O^^C1
M7'^Z_E9]+?$?\_$=O1117(>B%%%% !1110 444C,%4DD  9))H 6BN9O/B'X
M/L)C#=>(].213@J)PQ'Y5;TGQ?X=UV7RM+UJQNI,9V1S M^76@#;HHHH ***
M* "BBB@ HHHH **** "L3Q,U\ND-_9_F^>74#RA\V,\UMUEZYJG]D::UWY7F
M88*%SCK50OS*QAB>7V,N9V5MSR;7;F?2;I$U02_:)$WJ&.X[<^O:L&7Q Y)$
M, 'NQR:Z+Q!<Q^(-06^O8T4HGEJH; QG//YUE&[TRS^YY>1_<7)KVJ?PJZU/
M@JOL/:/V:<O4S/.U>\^YY@!_NC:*V=!\!ZCXA>1VNX85C8!B^7;GTJA-XAC4
M?NH6/NYQ4VG:_P")7WPZ,)U\T@M]GBW$_CCBBHY<ONZ'9@K^U7M(>[Y;G<?\
M*K/_ $%Q_P!^/_KT5D;?'G_44_[Z-%<=ZO\ .CW[4/\ GVST_6-=TOP_I[7V
MK7T-I;*<;Y6QD^@'4GV%>?2_'_P1%*\:RW\H4X#I;?*WN,D']*\,^)/B:_\
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M?B/\+_&>C?V9JFHWGDB590T5NX8,/0E3C()% %OX(?$"Z\4:7<Z1JLYGU&Q
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M)Z9[9KO?VAM%U'45\.IIFFW5TL*SAA;PM)L'[O&<#CI^E %G]FS_ )%76?\
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:SR23U-?5B@*,"@!:*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g876714g36g59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g876714g36g59.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  D T8# 1$  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#YTKX<_O@*
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
3 H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g876714g68a77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g876714g68a77.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !+ -0# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
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MXL^/_P!K:V&A?! W'A3X>W+M;ZK\3]2@:&2:+E73286P[L>1Y[!54YVG(!H
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M>^N#]^>4CJQZ#^ZH51P!0!Z70 4 % !0 TNH8*6 9LX!/)H =0 4 % !0 4
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MBK]IG2]0EDN+WX,? F)5>Z\4:I+_ &=J^OP]<0;R/L=JZ\F5_P!XZD!0H+8
M,B]_;S_9V^!FC:=X(^&:/XQO8O\ 1].\,?#_ $YKGS']I !&Y)Y+!F<G)()Z
M@'Y^?M#_ !"^(/[6/[>7@#3[CP@_PR\6V<FFZ99:5JTGVI[,"9KI+BX78O\
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MU_%+6['X*_#CX>^)K_PU<1PWFJZQ8:?*]OJ#DYC@\X+Y:1H0&;<PRVW. OS
M'4?L4?\ !,Z#X4>%1=_%F]_X22^O)HK\^$$G9](M9E'RM<1@[+J5<X!8%%^;
M:&SNH ^V_''@'P]\2?!^H^%?$VDV^L>'M0B$-SI\X/ER(""!P00054@@@@@$
M8(H Y_X2? 'X=_ G3Y[/P%X1TWPU'<8\^2TC)FFQT$DK$NX'8,QQF@!WQ9^
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
>4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g876714g69i42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g876714g69i42.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !S ,D# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
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M91'P0\+CPFWAQ!>)I_V"STY"MP?,C2UE>6!U;&=ZNY;)R#@9'JK(=V<OXO\
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M26Z16EQ]E01^1)')$0T<",2#$HY)R"<\X(+!<[X# JA"T % !0 4 % !0 4
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MVNK?3'M ;:8QW$-H4_=2E5;:X7HVUD;!YPP/0B@#2JA!0 4 % !0 4 % !0
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MJK(DK6'C"QN_%VK>'!%/!J.G6UO>-YJJ$FBF,@5XR"20&B=3D#!'H0260['
M7?[2OA^/3IM3M] U_4](M;8WU_J-G! T5C:>9(B7$@,P9D=8FE C5V$9#,JY
MQ4W0[,VM,^+C:YXCO],TKP3XAU*RL=1_LVYUF&33UM(Y $+OA[I92BAP21&2
M1G )XIJS$TS;^)'Q#T?X5^%+CQ!JZ3R6L3*BP6B*TTK$]$4L <#<QYX56/:F
M] 2N8OB?QZD'BYM)L_A_K7BZ\TA(K[[78'3ECM7E66-2IN;J)@^P2@E1]UR,
M\D5.X69-HOQ3D\1^*;[2;'P9X@FM+&^.GW6L&2Q6TBE"*[94W7G$ .HRL9YZ
M9'-4!U7B;7]-\(>']1UO5)?L^G6$#7$\@4N0JC)PHR6/8  DDX'6DP.8\(_%
M!?$NMKIEUX5\0>&;J:V:[M3K,$*K<Q*RJ^#%+)L8%T)238^&SMX.%=(#M-T;
M'IG-%T+4<#'CVIZ#N9&M^*;'0M3T"PN(IGFUJ^;3[<QJ"$D6VGN27R00-ENX
MR,G<5XP20DT/4V%="^ "&JR26@ H * .&^+^A7FJ^%X;_2;=[G7=#NXM6T^*
M(@/+)$?GA4G@&6(RP\]I3R*B143YP^*?P:\6W>@6L<>B7^H:Y#HIO[:]T>WL
M9'.N3S2RW;/-<[G@5"8BC0;'(RH?Y%%18NYZ5K'P9D-A)K6B:3!I7CR?7-0D
M37A&/M,,$LUR$8OU\K8\;;.G.=N<FKL1<Y:W^'UTWA2R@T_X6W6C^2;&3Q1:
MO<0++KP5V$\)VR%;H@GS3)(P\P?)SO8!-=@-WP+HVL_#_P 3SZ]:>"=5M?"D
MLUY:Z;X=LA 9M/BDBLSY@B\T)'')+;3$1J?E\Q20NY@!7#<S_#/P_P#%UB^B
M:7_8<EGH?BD0WGB&&:2-_P"S+FV<N=P#$2?:$6WA(7((B)/7-#8T<IX,^"WB
MRTTK5H+[3M337)_#NH66L7(M;2&/5;F2 HN^X24RW)9SO1W *C.=A)4JX,^E
MO <_AZST[4- \,:;%I>FZ%=-8&WM;5;>W63:LKB-5P#S+R0/O[NX-4A'C7A7
MPAJ5M?>"(H/#OBBWU;2]5>:ZGU"]+Z7'"3()'$4DS*&*.0AB0,"W92U '?WV
MM:MX>\<MXDC\):OJ^F:SH]M:/'9B'[3936\MPZB6-Y%X<7) *D[2G. 0: .T
M\*ZWJ.HV%JVKZ'+HE_+ )Y;;SUN(X"6($9D7 9P "V 0,X!8<EB.&^-WA'7]
M2O-(U/PHKQZK.DVAWL\3A&BLKI<&<9/+0RK%(.X'F8^]RI#1POCCX;ZMX5U#
MQ?%X6TGQ')<:CIUI%X=DT/5#:VEA-# ($69/.0;4,<3G>K@KD $Y4Q8:=S7\
M$Z)<^&_&'B1]6T'Q7-<W7B!KR"\TZ\F2PDC:.(*[1+.J$;E;(9#D=0:I#9+^
MT'\._''BZVUFZT8Z5J=F-(DM;#3KOS1-#.X<2R)@[2[(50%ONJ& QO;(U<2=
MB>_TF_MO'NK:AK^A^([^2ZTVQC%QX5OKBWMC(GG^8,)/&3@NN-P)P>M"5@9B
MR>#-2@\<F70O#GB33]8N_$T&I3Z[=ZC&;)+'?&]PBHLGW9(T:/RC&6WON)(4
M,#J'0]<^*FAZAXC^'VJ6>EQ1W&IJ(KFU@G?8DTL4J2I&S=@Q0*3V!JF2MSSO
MXB>(_%OCSP1JVDZ7X U33UGM8UNWU-[8R@-/$LL4,(E*3L(3._S.L9*HOSAR
M!**./^$7P,CN;R;3?%7A6>[\*VM[J4FGV7B"ULPBQR1:=Y9-O;*L"AF2Z8(J
M *<D@/R1(1S\_P +?%4_B?0KB\\/:H9]$GTN+1Y[2VL9U2UCN%:;S;B??/#L
M7>-D)C++MY?<P"*+!^&_B;3GT2?3/A](_CK3[K5IM1\2W$L21ZG*UA?QVS,Z
MR[Y%DDEAQNQY0.WY<TAG=_LR^ =0\">(O%L9TS5=,T&YMM/>U74K2QLQ)<#[
M0+AT@LU5%ZP@EP7. 2S#;BD]27L?0%:$'FGQ.^(OB[P1K>BVNE>%]%UBPU>]
MBTZWN+W79K.19W21_GC6SE 0",_,'))/W>]2W8I*X[6OC5I>A^$O%%U+>:%?
M>*_#>DW&I:CX=TW6$GDA:*(N8RVQ7520!O:(=<[>U%PY3L)O%FEPV.KW7VV"
M:+2=XOO(D#FW98Q(R. <JP1E;:<'# ]"*HD\Q/QX\0Z5X>_MG7? ,UA:7MG%
M<:3'::A]IDGEEGA@AMKC,2+!*[W$6 &D&/,.?D(J.8KE-G3/C%=C2O%":UX?
M%AXET!X8Y=)LKW[4ETTZ@VPAF9(]WF,WE_,BX=6'0 E.06+6E?%Z.\^"EC\0
M;G2V@:YTV.]&EPS>:QD< ) KE5#$NP4,0!DCI3YM L9/_"T_'T=Z^CR_#53K
MS20>3+!JSOI)AD25C))>&V!0H82K((F;,D6,A\@YA\I)>?&^[L/!^G:K)X4N
MY]0FU8Z1>6MI.)+>R=+K[/+(UP54&,'E?EW,2%VJ=VTYA6.G\<^*_$&AW6F6
M/AOPP/$-]>^:[275V;.SMDC"Y,LPCD(9BP"J$);#'@*31S!8X&3]H76+[PBO
MB;1O TUWHUII1U75)K[4!:^2%>59(;8^6Z7$B>1(QRT:8,9W_/@',/E-&/XZ
M7U]J\UQ8>&!-X/M;^TTRZUJ>_P#)G$UP(L-';^4=\:-/$KLTB$'?A6V&CF%R
MB^&OCM<Z[XBTF.?PVUAX8UR^NM-T?66O [W,\"R,?,@V#RDD$$QC;>Q8(,JN
MX4<P<IU7Q1\<7O@+0+*[T[3+?5[^]U*TTR"VNKQK6+?/,L09I%CD( +9.$)X
MJR2./XACPOID$OQ#NO#7@Z\NK@PVD2:[YT4XPN-LDT,!+Y)&P*<<')S@ &[_
M ,)9I&9!_:ECF.[6P<?:4RMRP!6$\\2$,I"=?F''(H Q/'?Q)M_"G@ZSUO3;
M8>(IM3FM[72K:TG4)>RSD"+$O*K'@[R_("@D9X!3=AI7.3G^,_B:"YM-!;P,
MJ>-+F]GMX["74G33Y((H8YGNH[LV^YX\2QQ\19\PE2 %+5/,5RE;Q+^TI:Z)
M\*=.\6VN@SWNI7C2I_8CW"QO"T#LEWYD@# +$R.N[!#,448+BCF#E.T^(/CV
M_P#"DFB6&CZ*NNZ[K-V;6TM9;K[+"H6-Y))99=CE$54/1&8EE 7FCF%RG)ZK
M\9/&-CI<EQ%\.7\[3[2>\U7[;J9MK>)8I)$V6TS0$7#.(FD7(C78R%BN[%',
M%C6M?C,-1\=>$]#M-!O#IWB#2WU./5KD^4B81'6((02[[7RW("\?>)P#F#E(
M/B5\7-<\"'6+VT\'/J?A_0K$:CJFI3WWV4F/YRZVJ&-A/(B(68,\8^90&).
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MP_J5II\7A7PCJMUJ=KJ4%T6FOE9)TMHC%M'EE!<G>2Q!,2XSN.VK"N=W\8O
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C0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 12,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">enGene Holdings Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">A1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">4868 Rue Levy, Suite 220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Saint-Laurent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">QC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">H4R&#160;2P1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">332-4888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001980845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENGNW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d876714d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d876714d8k.htm">d876714d8k.htm</File>
    <File>engn-20251112.xsd</File>
    <File>engn-20251112_def.xml</File>
    <File>engn-20251112_lab.xml</File>
    <File>engn-20251112_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>23
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d876714d8k.htm": {
   "nsprefix": "engn",
   "nsuri": "http://engene.com/20251112",
   "dts": {
    "inline": {
     "local": [
      "d876714d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "engn-20251112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "engn-20251112_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "engn-20251112_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "engn-20251112_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 31,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 27
   },
   "report": {
    "R1": {
     "role": "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-11-12_to_2025-11-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d876714d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-11-12_to_2025-11-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d876714d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "engn_DocumentAndEntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://engene.com/20251112",
     "localname": "DocumentAndEntityInformationLineItems",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "engn_DocumentAndEntityInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://engene.com/20251112",
     "localname": "DocumentAndEntityInformationTable",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "terseLabel": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "terseLabel": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://engene.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>24
<FILENAME>0001193125-25-283182-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-283182-xbrl.zip
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M%T2VJD2VIF9RF.U2E'[T@\H)+0ZH6'J <G0R"@)744ZK#$43(0,8&Z4;Y[$
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MEN1 XWN@]@JT568];XS!DJ6,3=!+ 2^YIZ&:W0S1IFX316QP8IXR;(:<+ D
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MKNY9['N[#*H\,X,J"PS:IG+Z5OE3J;Z4!K5]3ZJ#(=MJT)XNW.A]ADSI!JS
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MZ?ZIT:5K1,K(/+Y&-14!,3>[,08Y*%O3"Q?K+::61?:>*#_ARQ=5KX> ,I5
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MZ\"N'1#MRUJ=L3G),:CFHVC&MN-UDE[O-?N<$=%K_2:IP.%A#E!$1ZOF^1G
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M]>M^>3I'Z,57%<KDR\@DE^KW"648>7!V%^&?C*X8BGHQ3U4:UE3).J&L!D
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MUDGR_."I%Q)0J#JS%:_Y]O8_]>\G)UCBS%(#/:^0+%;&0%^66FIAUIC!*LM
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MI8$]*7@,%&'7#,+)+/9;E'HJ7FK? [0VWIJ *\Q"XK*2KX:G%B-Y0:M.W<Z
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M.HDFR *3+E/$'*O1IGW_,'8E;O) 8V71CJDR+;HO3@\?@IF3QCU>EY<!W%(
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M]2CAIR!A9O5J=* 3YJ<'^B(;WAPX?5FNU-I;H86I!#K,*"U!!U68G*JXV5I
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M'^#V<(K)_/VA9"0E'I>^0PNO@&'L<U(8:YC6Z$YAS0DTVBBUG.-6\W"S--/
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M1)4B/"#7$3##N B1'TZB2T+,D )UF0Y0+:F78'_WHW(4Y 7^%O^9QF6I?]5
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MI^ _,:9;R^<Y2WQ].3:-;"WB?TV3 J4R2O5H$ ?G>3H%/E; WH08OLH+#N3
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M0?"GLX/@O_WZ^M.;?\*'OW_Y\/[5_P=02P,$%     @ \X1N6SAZ]M?*.@
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MP""7$5+B5\A(F'(DB!2 /Q,E*Q#E(-%#O0;(BT_"-.DX7@"+&<+C./O;,/_
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M^X'@K:KKQ4/8JL5N=\>;F9Q7E#VLLJG=V'/C5;?+"L# &VR2AY9-DGB\#H#
M!2Q3G6$= @WP!0;*]-'T,4[E[ZK>CH'58Q9;T$##CO^[D&"!>:IH4A &@M8
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MGQ\:1RG<,27G@,B2%9@(7(**1?+"!.V5V8K24/QKK-0J73Q$<MXJ]8249%R
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MN1%(1G&8KSKD U7N5A5@R(8+[.GU$==+&*'"?Y K:".B49 DEZ2@1IUE81O
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M[[DTMXXI\1:GQ?J1E/3*)"HIE0I49,TE1W+IJWW5F&/\&.?*XT\NWL(]"09
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MV#_KPP=\!;^AB]M__688G/;.8=V#]T$+SWIWI_=S_[1WP>M6O[5QL;0@WET
MD&9,/1W@^F')O;,S!#'B,$ ?]DT;[ _MPZ43XGT);)B2$-GH#Q&_7U]>,O&X
MOCD[ZY_T$<<: ,G3F"L/G]\@-!#-N_T+@\^:7)WV &F)E)SWW_8U>KWKXO&^
MW]T9$$!PJW@2>C)Y#&[J!9P\0 #>'3+1 YKS*;1&4 270W,1C+IP;?J +_ [
M8.;[!^ EMVT*JGX345R U>Q])M_H:/V<RP"3WR"-N2!\BOWE)'_#YJGDA:UP
M8A/'4PF%)ML9V8Q,"8UJC.W#*5(S5J2P/JV$XTHEZ)0SM&E]*2FIE!G:' ]<
MD=OCE*Q=^.HRC3#P=ARISNQL&";]0;IMJ1JV #ML2")/.T'()BO)2"@;%R(I
M=:1^B?"I2D-2]0\T;ZI8[=&J4Q%)/35";+T8K%]Z9EX4HE"BDM:RO"6.W+(V
M;QK(>$W'0Q2QZBUOY)AGC%/63EXHFSQE7K*XZ@PU[793_935"$X'FQI+V/UA
MFV_ ^N>@!Z09&3MQGJONZQZ)81=(^8F)G??.AL'Q>??B;__Z:LUTS[^9Z3Z'
M0@$C AY]@3SI'7.]3D5K(YU]XMY^*76]3"@J=[PLE?)7F"K56)AL&H^CG.L
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M<LWFY$[,*.QT-NA?79]60D2RTCTY[_:^3/F(1P0()B>[Y]V3W=MN9O\,\"8
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MM!C#,TX]F=0KU1-$+[_!Z]?-^_[ZBBR5$HAR-^7%GZ6\.&%^#.JOBCI81O1
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MW3C(Y3.K4LF37?PY4'BH?D3T?U!+ P04    " #SA&Y;]AT^6$H0  "Q0P
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M:^X1VI,@>BN"%OM'N_6JO=/:W&JW=G8V-IZ;.:?\;F]NS_:S$SJ=3ELA*6B
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M;F![@53XS+U(J1-<0,TC]%QRE44AG>S16S*DQR9"OF12SZR6OV+8HU-,,QN
M,R"VJ\B3@;23""_>ZMG5XE?4"]L;45H6;B<([.0/N!&)^0YDT3B<@<.'?B9*
M]VS7@70)>ZZ<Q2+B03ICB9T?+:VMUP*\Z8V! G17!4"%O9<ASP+L&Y7ZD)1S
MT9FO/=AU78]$A-@^9('\,Y-F^LKG(<A0E^H!'F*VQJ9CZ8U=NW(L M\,V&&O
M-TM2.Q'%W4B+Q=]-*A)-]A$0.!02?:I]2H]?K.:YK>97-!NCA:[AQG&2 &T
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MS=1(F\)&D_6UV4(ZSVR<Z3Q7B4A=I)A*I,!+G<Y^?7][AX11T%@?-#EL6OR
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M^G'3O<11T4_*3]0+Y -@%S4LE2F4H\[:NWC!C6,.F9&*3$JS-LO&+H0BHA
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M4(8Q-4MM\TZ?6"CNN,]NAA3;<GY"P3SA/Z7,JL75!8JOWP!02P,$%     @
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MG/1!UB"$A.J3,BAI;T!K*+0(YHYJBP<NY"OUC=#9(9I^+[(\\C]02P,$%
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M!P"TQP4,#*3ZNT#,17LQD#7';!6Z.5N><.ME".^<,R94C[-(=C$PI72^/G$
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M !               ( !0Q8  &0X-S8W,31D97@Q,2YH=&U02P$"% ,4
M" #SA&Y;.'KVU\HZ   <  $ $               @ $2UP  9#@W-C<Q-&1E
M>#0Q+FAT;5!+ 0(4 Q0    ( /.$;ELXHMF%J@X  $M4   0
M  "  0H2 0!D.#<V-S$T9&5X-3$N:'1M4$L! A0#%     @ \X1N6_8=/EA*
M$   L4,  !               ( !XB ! &0X-S8W,31D97@U,BYH=&U02P$"
M% ,4    " #SA&Y;&#_JVL<.  "P*@  $0              @ %:,0$ 9#@W
M-C<Q-&1E>#DY,2YH=&U02P$"% ,4    " #SA&Y;.9005)L#  #K#0  $0
M            @ %00 $ 96YG;BTR,#(U,3$Q,BYX<V102P$"% ,4    " #S
MA&Y;!4_VQ]8%  #!-P  %0              @ $:1 $ 96YG;BTR,#(U,3$Q
M,E]D968N>&UL4$L! A0#%     @ \X1N6Y,Q'_C7!P  15L  !4
M     ( !(TH! &5N9VXM,C R-3$Q,3)?;&%B+GAM;%!+ 0(4 Q0    ( /.$
M;ELTIK&R=P4  !,[   5              "  2U2 0!E;F=N+3(P,C4Q,3$R
>7W!R92YX;6Q02P4&      H "@![ @  UU<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>d876714d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="engn-20251112.xsd" xlink:type="simple"/>
    <context id="duration_2025-11-12_to_2025-11-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <startDate>2025-11-12</startDate>
            <endDate>2025-11-12</endDate>
        </period>
    </context>
    <context id="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-12</startDate>
            <endDate>2025-11-12</endDate>
        </period>
    </context>
    <context id="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-12</startDate>
            <endDate>2025-11-12</endDate>
        </period>
    </context>
    <dei:EntityTaxIdentificationNumber
      contextRef="duration_2025-11-12_to_2025-11-12"
      id="Hidden_dei_EntityTaxIdentificationNumber">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-11-12_to_2025-11-12"
      id="Hidden_dei_EntityCentralIndexKey_duration_2025-11-12_to_2025-11-12">0001980845</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="duration_2025-11-12_to_2025-11-12"
      id="Hidden_dei_AmendmentFlag_duration_2025-11-12_to_2025-11-12">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="duration_2025-11-12_to_2025-11-12" id="Fact_1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-11-12_to_2025-11-12" id="Fact_0">2025-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-373">enGene Holdings Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-11-12_to_2025-11-12" id="Fact_2">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-375">001-41854</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-376">4868 Rue Levy, Suite 220</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-377">Saint-Laurent</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-378">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-379">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-380">H4R&#160;2P1</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-11-12_to_2025-11-12" id="Fact_4">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-11-12_to_2025-11-12" id="Fact_5">332-4888</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-383">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-384">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-385">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-386">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-387">Common Shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-388">ENGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-389">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember"
      id="ixv-390">Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember"
      id="ixv-391">ENGNW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-11-12_to_2025-11-12_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember"
      id="ixv-392">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-393">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-394">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
